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1. Introduction
Hypoxic ischemic encephalopathy (HIE) currently constitutes one of the non-excluding causes
of child cerebral palsy (CP) and, together with prematurity, is potentially preventable. For this
reason there is an increasing interest in prevention policies as well as in research on neuro‐
protection therapies that minimize cerebral lesion and concomitant disabilities.
In the last few decades there has been an explosion of studies employing either animal models
of global or focal hypoxia or cell cultures investigating the preventing effect of many chemicals
on neuronal lesion. Recent clinical research has shown that certain pharmaceuticals have
neuroprotective effects, suggesting that their use could be generalized for clinical practice in
a near future. However, the use of some of these chemicals, such as nicardipine (calcium
blocker) or magnesium (blocking NMDA-receptors), has been investigated in clinical trials
showing no beneficial effects while causing severe hemodynamic adverse events. Therefore
there is no generally accepted standard of care in the brain-oriented pharmacologic therapy
for full-term neonates sustaining cerebral hypoxia–ischemia (H-I). In fact, neuroprotective
treatment for HIE in the clinical practice is limited to the application of hypothermia in the
newborn which is accepted now as a meaningful therapy, since no pharmaceutical has shown
any benefit when administered by itself yet.
Future advances in the understanding of preconditioning may lead to the administration of
neuroprotective agents earlier before childbirth. Although most of these neuroprotective
strategies have not yet entered clinical practice, there is a significant hope that further devel‐
opments will allow to incorporate them besides hypothermic neuroprotection. More specifi‐
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cally, maternal administration of allopurinol (xanthine oxidase inhibitor/ anti-oxidant) has
been proposed as prebirth treatment when there is suspicion of an adverse event eliciting
perinatal asphyxia.
Since it is conceivable that hypothermia postpones secondary energy failure, application of
hypothermia immediately after the hypoxic event could prolong the window for pharmaco‐
therapeutic intervention; furthermore, there is accumulating preclinical evidence that adjunc‐
tive therapies can enhance hypothermic neuroprotection. The question that still remains is
whether a combination of therapeutic agents would be more efficient in reducing brain damage
due to hypoxia-ischemia than applying just one pharmaceutical. The hypothesis is that
combinations of therapies intervening at different levels in the cascade might lead to more
prominent reduction of brain injury.
In this chapter we review the mechanisms of action of chemicals that have shown potential
neuroprotection effect, with special regard to those already approved for use in the newborn
and show no side effects. Finally, we propose a model of off-label combined neuroprotective
therapy using a staggered design according to the severity of the asphyxia /encephalopathy.
2. Neonatal encephalopathy
The incidence of birth asphyxia is 9.4/1000 live term births whereas the incidence of neonatal
encephalopathy secondary to intrapartum hypoxia-ischemia (H-I) is very low, estimated
between 0.27 per 1000 (Palsdottir et al, 2007) and 1.5 per 1000 live full-term births; and about
15% to 20% of affected newborns die in the postnatal period, and an additional 25% of the
survivors exhibiting permanent neuropsychological deficits (Kurinczuk et al, 2010). Birth
asphyxia often appears to be a secondary symptom of an otherwise sick baby; thus, it is not
the primary cause of CP in the majority of cases. One study of children with CP found that in
only about 8% (15/183) of all the children with spastic CP was intrapartum asphyxia the
possible cause of their brain damage; and the contribution of intrapartum events and obstetric
mismanagement to overall CP rates is probably less than was previously throught (Blair &
Stanley, 1998). In fact, due to this type of research, the term birth asphyxia has been replaced
with the term neonatal encephalopathy because this later term does not imply a causal
relationship (Fehlings et al, 2007).
Perinatal asphyxia can be defined as the injury caused to the fetus or newborn as a result of
both reduced oxygen (O2) supply to the brain and the sustained reduction in blood flow due
to an inadequate cerebral perfusion. The term “asphyxia” is not synonymous with HIE despite
been closely related: “asphyxia” is the cause whereas HIE is the effect. Besides, asphyxia does
not always produce brain damage. HIE is defined as the neurological syndrome occurring in
the newborn after a hypoxia / ischemia episode that affects consciousness in different degrees,
with decrease of spontaneous movements, tone and reflexes, as well as the appearance of
convulsions in the most severe cases. Hypoxic-ischemic events may cause multisystemic
failure with impairment of pulmonary, cardiovascular, digestive, renal, hematological and
metabolic functions, constituting the post-asphyctic syndrome. However, it is important to
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emphasize that the clinical features of hypoxic ischemic encephalopathy are nonspecific, and
a diagnosis of perinatal asphyxia should be made with caution and only after careful consid‐
eration of all data collected in the clinical history.
The essential criteria required to define an acute intrapartum hypoxic event as sufficient to
cause CP were established by by both the American College of Obstetricians and Gynecologists
and the American Academy of Pediatrics, and the International Cerebral Palsy Task (ACOG,
2003), are listed as follows:
Essential criteria (must meet all four)
• Evidence of a metabolic acidosis in fetal umbilical cord arterial blood obtained at delivery
(pH < 7 and base deficit =12 mmol/L).
• Early onset of severe or moderate neonatal encephalopathy in infants born at 34 or more
weeks of gestation.
• Cerebral palsy of the spastic quadriplegic or dyskinetic type.
• Exclusion of other identifiable etiologies such as trauma, coagulation disorders, infectious
conditions, or genetic disorders.
Criteria that collectively suggest an intrapartum timing (within close proximity to labor and
delivery, eg, 0-48 hours) but are nonspecific to asphyxial insults
• A sentinel (signal) hypoxic event occurring immediately before or during labor
• A sudden and sustained fetal bradycardia or the absence of fetal heart rate variability in the
presence of persistent, late, or variable decelerations, usually after a hypoxic sentinel event
when the pattern was previously normal
• Apgar scores of 0-3 beyond 5 minutes
• Onset of multisystem involvement within 72 hours of birth
• Early imaging study showing evidence of acute nonfocal cerebral abnormality
Neonatal encephalopathy is a clinically defined syndrome of disturbed neurological function
in the infant at or near term during the first week after birth, manifested by difficulty with
initiating and maintaining respiration, depression of tone and reflexes, altered level of
consciousness, and often seizures. Sarnat and Sarnat (Sarnat & Sarnat, 1976) were the first to
define this syndrome as neonatal encephalopathy following foetal distress (TABLE 1). The
clinical features and severity of encephalopathy have been well defined. They distinguished
three stages of encephalopathy: stage 1, or mild encephalopathy associated with hyperalert‐
ness, sympathetic overdrive, and a normal EEG; stage 2, or moderate encephalopathy marked
by obtundation, hypotonia, multifocal seizures, and an EEG showing periodic or continuous
delta activity; and stage 3, or severe encephalopathy in which infants were stuporous and
flaccid with an isoelectric or periodic EEG.Infants who did not enter stage 3 and who had signs
of stage 2 for fewer than 5 days were normal on follow-up, but persistence of stage 2 for a week
or failure of the EEG to normalise predicted later neurological impairment or death.
Neuroprotection in Perinatal Hypoxic-Ischemic Encephalopathy — Pharmacologic Combination Therapy
http://dx.doi.org/10.5772/57459
125
State 1 Mild Stage 2 Moderate Stage 3Severe
Level of Consciousness Hyperalert Lethargic or obtunded Stuporous
Neuromuscular Control
Muscle tone Normal Mild hypotonia Flaccid
Posture Mild distal flexion Strong distal flexion Intermittent decerebration
Stretch reflexes Overactive Overactive Decreased or absent
Segmental myoclonus Present Present Absent
Complex Reflexes
Suck Weak Weak or absent Absent
Moro Strong; low threshold Weak; incomplete; highthreshold Absent
Oculovestibular Normal Overactive Weak or absent
Tonic neck Slight Strong Absent
Autonomic Function Generalized sympathetic Generalizedparasympathetic Both systems depressed
Pupils Mydriasis Miosis Variable; often unequal;poor light reflex
Heart Rate Tachycardia Bradycardia Variable
Bronchial and Salivary
Secretions Sparse Profuse Variable
Gastrointestinal
Motility Normal or decreased Increased; diarrhea Variable
Seizures None Common; focal ormultifocal
Uncommon (excluding
decerebration)
Electroencephalogram
Findings Normal (awake)
Early: low-voltage
continuous delta and
thetaLater: periodic
pattern (awake) Seizures:
focal 1-to 1-Hz spike-and-
wave
Early: periodic pattern with
Isopotential phasesLater: totally
isopotential
Duration <24 h 2-14 h Hours to weeks
Table 1. Sarnat and Sarnat’s [236] Clinical Stages of Perinatal Hypoxic Ischemic Brain Injury
The diagnosis HIE has often not been proven and has been assumed from a variety of clinical
markers that do not accurately reflect hypoxia and ischaemia of either acute or chronic origin.
Over 75% of cases of neonatal encephalopathy have no clinical signs of intrapartum hypoxia.
Dammann et al (Dammann et al, 2011), under the title “Neonatal Encephalopathy or Hypoxic-
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Ischemic Encephalopathy? Appropriate Terminology Matters” propose that by simply calling
“neonatal encephalopathy” what is now called “HIE,” we might not only help reduce the
number of unjustified convictions of obstetricians, midwifes, nurses, and hospitals but also
increase the amount of much needed research in perinatal brain injury not necessarily related
to the hypoxia-ischemia paradigm.
Although in many newborns who have cerebral dysfunction, the brain injury may have
occurred before the onset of labor and delivery, there exists a relatively small but clearly
identifiable group of term newborns who sustain significant intrapartum H-I cerebral insult
and who subsequently develop an acute encephalopathy during the first week of life. The
Sarnat evaluation of staging of encephalopathy by clinical examination correlates well with
subsequent neurodevelopmental impairment in infancy and childhood (Robertson, 2003;
Badawi et al, 2005; Ambalavanan et al, 2006). The presence of abnormal neurologic examina‐
tion results in the first few days of life highly predicts a brain insult in the perinatal period.
Neonates with mild encephalopathy usually do not have an increased risk of motor or
cognitive deficits. Neonates with severe encephalopathy have a high risk of death (up to 85%)
and an increased risk of CP and intellectual disability among survivors. Neonates with
moderate encephalopathy have significant motor deficits, fine motor disability, memory
impairment, visual or visuomotor dysfunction, increased hyperactivity and delayed school
readiness (Shankaran et al, 1991. Robertson, 2003; Marlow et al, 2005; Gonzalez& Miller,
2006. De Vries & Jongmans, 2010).
3. Neuropathologic aspects of hypoxic–ischemic brain damage
3.1. Gestational/perinatal age
H-I insults during critical cellular and tissue differentiation processes have a serious impact
on brain maturation. Thus, the gestational/perinatal age of the infant is one of the main
variables in determining the neuropathological picture of H-I brain injury. For this reason
alone, the developmental stage at which a H-I insult occurs is of great importance. However,
the mechanism(s) underlying the neuronal damage and death triggered by H-I in the devel‐
oping brain leading to various forms of neurological disabilities remains inadequately
understood. Due to selective ischemic vulnerability, the damage affects the gray matter in term
newborns and white matter (WM) in preterm newborns with the typical neuropathological
aspects of laminar cortical necrosis in the former and periventricular leukomalacia (PVL) in
the latter (Volpe, 2003).
Reactive oxygen species (ROS) play a pivotal role in the development of PVL. The major type
of injury involves cerebral white matter and the principal cellular target is the developing
oligodendrocyte. The specific phase of the oligodendroglial lineage affected has been defined
from the study of both human brain and experimental models. This premyelinating cell (pre-
OL) is vulnerable because of a series of maturation-dependent events. The pathogenesis of pre-
OL injury involves two upstream mechanisms, H-I and systemic infection/inflammation, both
of which are common occurrences in premature infants. This differential susceptibility to
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injury can also be related to the development of interneuronal connections and excitatory
glutamate receptors that create the possibility of excessive neurotransmitter release and
receptor overstimulation. Moreover, most forms of H-I in neonates cause injury to selected
areas of the brain rather than the entire brain (Johnston, 2001; Johnston et al, 2001). Most
importantly, elucidation of these factors has led to delineation of a series of potential thera‐
peutic interventions, which in experimental models show marked protective properties. The
critical next step, i.e., clinical trials in the living infant, is now on the horizon (Volpe et al, 2011).
3.2. Developing human cortex
The subplate zone (SPZ) is a transient cytoarchitectonic compartment of the fetal telencephalic
wall, situated between the fetal WM (i.e. intermediate zone) and the cortical plate, and is the
crucial laminar compartment for the development of the human cerebral cortex. The subplate
contains numerous neurons of various morphological types and molecular phenotypes,
including differentiated projection (glutamatergic) neurons and local (GABA and peptidergic)
interneurons. The developing human cortex goes through three major early stages of func‐
tional development: (1) between 13 and 15 postconceptional weeks (PCW): initial-transient
fetal circuitry, centered at the SPZ, which is endogeneously (spontaneously) driven; (2) 15 and
30 PCW: perinatal dual circuitry (co-existence of endogeneously driven subplate-centered
transient circuitry with developing cortical plate-centered permanent circuitry), that slowly
disappears towards the end of gestation and during the early postnatal period; and (3)
postnatally established permanent (externally driven) cortical circuitry, centered at the cortical
plate (that is, developing cortical layers I-VI). While the SPZ disappears during the perinatal
and early postnatal period, numerous subplate neurons survive and remain embedded in the
superficial (gyral) WM of adolescent and adult brain as so-called interstitial neurons (Judaš et
al, 2010). The growth of the axonal pathways preterm explains their vulnerability and plasti‐
city. In neonates the vulnerability is related to the intracortical circuitry. The neuronal elements
in transient fetal zones form a developmental potential for plasticity after perinatal cerebral
lesions (Kostovic & Judas, 2006).
3.3. Gender differences
This new information about gender differences in neuronal death pathways in experimental
models is probably directly relevant to gender differences reported in the response of infants
and children to brain injuries. Quantitative imaging showed that male premature infants are
more vulnerable than girls to white matter injury from intraventricular hemorrhage (IVH), but
girls are more vulnerable to gray matter injury. It follows directly from this information that
an infant's gender could influence the efficacy of neuroprotective agents and the cell types
most at risk. A striking example of this effect was reported from the prospective “Indomethacin
Intraventricular Hemorrhage Prevention Trial” (Ment et al, 2004). In this study, indomethacin
eliminated parenchymal hemorrhage and improved verbal scores in boys at ages 3 to 8 years,
but had no effect on girls. “It is becoming increasingly clear that gender differences are not
simply a result of hormonal influence but are profound properties of individual cells” (Fatemi
et al, 2009).
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4. Physiopathological and biochemical processes of H-I cerebral injury
The principal biochemical mechanisms of cellular death in hypoxemia, ischemia and asphyxia
are very similar and derive from O2 deprivation. Besides the main role of perinatal asphyxia,
a key factor in the genesis of HIE is the loss of “cerebral blood flow (CBF) autoregulation”, a
protective mechanism that maintains stable CBF velocity (CBFV) in normal infants, regardless
of variations of systemic arterial pressure. At the cellular level, the reduction in CBF and
oxygen delivery initiates a cascade of deleterious biochemical events. Clinical and experimen‐
tal observations demonstrate that HIE is not a single ‘‘event’’ but is rather an “evolving
process”, and reflect the evolution of a delayed cascade of molecular events triggered by the
initial insult (Fatemi et al, 2009).
4.1. Physiopathological mechanisms of cerebral injury
H-I injuries develop in two phases: the ischemic phase, dominated by necrotic processes, and
the reperfusion phase, dominated by apoptotic processes extending beyond ischemic areas.
This second phase takes place two - six hours after H-I insult, such latency constituting a useful
window in which therapeutic measures can be able to stop the evolution of cerebral damage
(Hammerman & Kaplan, 2000; Inder &Volpe, 2000).
4.1.1. Acute injury: Primary energy failure (associated with anaerobic metabolism)
There is an initial immediate phase (FIGURE 1) characterized by alterations in glucose
metabolism; the anaerobic metabolism is an energy-inefficient state, since anaerobic glycolysis
produces lactate and only 2 ATP, whereas aerobic glycolysis produces 38 ATP. HI rapidly
lowers the neonatal brain’s stores of glucose and high energy phosphates (ATP and phos‐
phocreatine), resulting in energy depletion and accumulation of lactate and inorganic phos‐
phate; and a metabolic acidosis develops due to accumulation of lactic acid, with local and
systemic consequences such as impaired vascular tone and cardiac contractility. In this phase,
the crucial event triggering a cascade of chain reactions is represented by ATP depletion
secondary to anaerobic glycolysis and metabolic acidosis induced by hypoxia. Reduced ATP
availability determines the dysfunction of ATPase systems, in particular Na+, K+-ATPase and
glial-ATPase. Na+, K+-ATPase dysfunction leads to membrane depolarization in neurons
mainly causing intracellular calcium accumulation, and sodium and water accumulation with
cytotoxic edema and/or cell lysis followed by inflammatory reaction with cytokines release.
Disturbances of intracellular calcium homeostasis result in activation of calpains (calcium-
activated proteases). At the same time, neuronal depolarization induces glutamate release which
tends to accumulate in the intersynaptic and intercellular spaces because of the dysfunction
of glial-ATPase (an astrocytic enzyme normally in charge of glutamate reuptake). Thus
extracellular glutamate increses due to both enhanced release and lower recapture. Glutamate,
a neuroexcitatory aminoacid, stimulates specific NMDA and AMPA neuro-glial receptors and
hence determines a massive intracellular entry of calcium that activates some endocellular
enzymes including proteases, endonucleases and phospholipases. Proteases degrade neuro‐
filaments causing cytoskeleton rupture and disintegration of the cellular body. Furthermore,
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excessive amount of glutamate can cause excitotoxicity leading to celldeath of neurons and
glial cells. These events involve major mechanisms of fast neuronal death (edema, inflamma‐
tion, necrosis) due to either direct or indirect neurotoxicity [mediated by free-radicals (FR) and
nitric oxide (NO) generated during the first minutes / hours of anoxic insult]. In asphyxiated
human neonates, the extent of depletion of high-energy phosphates, and the extent of accu‐
mulation of lactate, measured by magnetic resonance spectroscopy, correlate with the severity
of eventual neurologic impairment (Hanrahan et al, 1999).
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Figure 1. ACUTE INJURY: Primary energy failure (associated with anaerobic metabolism).
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4.1.2. Delayed brain damage: Secondary energy failure (associated with reperfusion)
Secondly, a complex cascade of pathogenic mechanisms associated with reperfusion (or
recovery of the blood flow) is triggered and this response is proportional to the severity of the
first response. The secondary cerebral energy failure, also known as "delayed injury" (FIGURE
2), occurs from 6 to 48 hours after the primary event and may continue for days or weeks.
Extended reactions from primary insults (eg, calcium influx, excitatory neurotoxicity, oxygen
free radicals, or NO formation) secondary involve mitochondrial dysfunction. This mitochon‐
drial impairment may lead directly to caspase-dependent and -independent apoptosis. This
second phase also has an undoubtable prognostic value since it is associated with delayed
neuronal death (apoptosis) during hours or days after the initiation of injury, and represents
a window for therapeutic intervention. The exact mechanisms of secondary energy failure
remain unclear but appear to be related to oxidative stress, excitotoxicity, and inflammation.
In this phase, recovery of ischemia increases O2 availability and hence activates xantine-
oxidase (via metabolizing the hypoxanthine formed during the initial period of HIE to uric
acid) and cyclooxygenase enzymes and generates reactive oxygen species (ROS) responsible
for oxidative cellular damage. Due to the increased intracellular calcium from the previous
period, the reperfusion phase shows a sustained activation of phospholipase A2 that hydrolyze
phospholipids and can damage cellular membrane and induce the consequent release of free
fatty acids (FFA), especially arachidonic acid (AA). Reperfusion also activates cyclooxygenase
that catalyses the formation of prostaglandins and generate -among others- superoxide free
radicals. The production of vasodilator prostaglandins that give rise to reperfusion of ischemia
and build-up of platelet-activating factor (PLF) in brain tissues. Collectively, these processes
lead to a surge of the superoxide free radical, which plays a central role in further production
of free radicals and other toxic compounds (Lorek et al, 1994).
4.2. Biochemical mechanisms of injury
Key players in the pathophysiology of neonatal cerebral injury are accumulation of cytosolic
calcium, oxidative stress, excitotoxicity, and inflammation leading to apoptotic and necrotic
neuronal death (Grow & Barks, 2002; Hossain, 2005).
4.2.1. Oxidative stress: Formation of free radicals (FRs)
Definitions of Oxidative stress: The imbalance between free radical (FR) generation and free
radical scavenging that leads to cell injury.
All biological systems that consume oxygen generate FRs, which are molecules with one or
more unpaired electrons in their outer orbit. They readily accept electrons from iron and other
metals to form more reactive radicals, which attack other biomolecules, especially lipids,
proteins, and nucleic acids, generating more radicals that damage the developing brain. In
aerobic cells, oxygen free radicals (reactive oxygen species –ROS-) are produced within the
cytoplasm and mitochondria. The three most common ROS are superoxide (O2-), hydroxyl
radical (OH-), and hydrogen peroxide (H2O2). Two important sources of ROS are the byprod‐
ucts of xanthine (derived from the breakdown of ATP) and prostaglandin synthesis (derived
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from the breakdown of free fatty acids). Low levels of ROS are indispensable in many
biochemical processes, including intracellular messaging in the cell differentiation and cell
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progression or the arrest of growth, apoptosis, immunity, and the defense against micro-
organisms. Interestingly, more recent data strongly suggest that low levels of NO and ROS are
involved in normal events such as gene transduction control (Kroncke, 2003). In contrast, high
doses and/or inadequate removal of ROS result in oxidative stress, which may cause severe
metabolic malfunctions and damage to biological macromolecules. Increased production of
ROS contributes to the pathogenesis of neonatal H-I brain injury. Acute restoration of blood
flow after ischemia leads to the production of ROS, which are directly toxic to neurons and
glia, and which may exacerbate leukocyte accumulation, microvascular thrombosis, and NO-
mediated injury (Matés et al 1999).
Under normal physiologic conditions, low concentrations of O2- and H2O2 are produced as a
byproduct of mitochondrial electron transport, a balance is maintained between the produc‐
tion of ROS and the capacity of the antioxidant enzyme system; however, if this balance breaks
down, ROS can exert toxic effects. The oxygen FR are destroyed rapidly by the endogenous
antioxidants: they are scavenged enzymatically by superoxide dismutase (SOD), catalase
(CAT), and glutathione peroxidase (GPX), and nonenzymatically by reaction with antioxidant
molecules, such as alpha-tocopherol (vitamin E), and ascorbic acid (vitamin C), glutathione
(GSH), b-carotene, and vitamin A (Grow & Barks, 2002). Treatment with the iron chelator
deferoxamine, N-acetylcysteine (NAC), or with allopurinol (a xanthine oxidase inhibitor that
also acts as a FR scavenger), attenuates H-I damage in the immature rat (Palmer et al, 1993;
Palmer et al, 1994). A recently discovered antioxidant enzyme family, peroxiredoxin (Prdx), is
also an important scavenger of FR: Prdx1 expression is induced at birth, whereas Prdx2 is
constitutively expressed, and Prdx6 expression is consistent with the classical antioxidant
enzymes (SOD, CAT, and GPX) (Shim & Kim, 2013).
It is recognized that during intra- and peripartum asphyxia the generation of ROS is increased
exceeding the capabilties of the protective mechanisms and causing oxidative stress. FRs
produced from xanthine by products and prostaglandin synthesis attack polyunsaturated fatty
acids (PUFAs) of the plasma membrane, increasing membrane permeability, endothelial cell
death compromises the blood-brain barrier (BBB), resulting in vasogenic edema and hemor‐
rhage. The mitochondrial respiratory chain is also a major source of ROS, and mitochondrial
dysfunction contributes to cellular necrosis as well. FRs are another example of the inability
of the immature brain to handle reoxygenation. Although FR concentrations rise during
hypoxia, a significant secondary elevation occurs during resuscitation.
The relationships between FR generation and perinatal brain damage are complex there are a
number of potential mechanisms of FR generation (Mishra & Delivoria-Papadopoulos, 1999;
Robertson & Finer, 1993):
1. Accumulation of intracellular Ca2+ and subsequent activation of:
• Phospholipase a2 leading to increased generation of oxygen FRs from cyclooxygenase
(COX) and lipoxygenase (LOX) pathways, and phospholipase C leading to IP3
formation resulting in release of Ca2+ from intracellular stores. Neonates also have high
concentrations of PUFAs that break down to form more oxygen FR (Shalak & Perlman,
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2004). ROS contribute to tissue injury by attacking the PUFAs component of the cellular
membrane, resulting in membrane fragmentation and cell death.
• Nitric oxide synthase (NOS) leading to peroxinitrite formation and generation of FRs.
NO is a weak free radical formed during the conversion of L-arginine to L-citrulline by
NO synthase (NOS). NOS is strongly activated during H-I and reperfusion, producing
a large amount of NO for extended periods. When combined with superoxide, NO
generates a potent radical, peroxynitrite, which activates lipid peroxidation. In addi‐
tion, NO enhances glutamate release (Palmer, 1995). The generation of ROS which
interact with endothelial cell-derived NO leading to the formation of reactive nitrogen
species (RNS). ROS and RNS target endothelial cells and neuronal cells, and both the
oxidative stress and the nitrosative stress have been implicated in animal models of
perinatal brain damage (Grow & Barks, 2002; McQuillen & Ferriero, 2004).
• Proteases leading to conversion of xanthine oxidase resulting in increased FR genera‐
tion.
2. Reduction of electron transport chain components including ubiquinone (a component
that undergoes autooxidation to produce FRs) (Turrens et al, 1985).
3. Release of iron from ferritin under the condition of depleted cellular high energy
compounds. Physiologically, iron is maintained in a nontoxic ferric state and is bound to
proteins (ferritin, transferrin). During H-I, free ferric iron is released from these proteins
and reacts with peroxides to generate potent hydroxyl radicals. In addition, free ferric iron
is reduced to a ferrous form, which further contributes to FR injury. Iron is a major
mediator of cell damage. Differentiating OLs are particularly susceptible to FR damage
because they are rich in iron, which is required for differentiation.
and
4. Increased degradation of ATP during hypoxia and increased substrate for the xanthine
oxidase reaction Hypoxanthine accumulates as a product of ATP degradation and cannot
be reconverted to ATP by the salvage pathway in anaerobic conditions. Xanthine dehy‐
drogenase is converted to xanthine oxidase through the activation of a specific protease
by calcium and this reaction produces ROS.
4.2.2. Excitotoxicity (Excitatory neurotransmitter release)
Definitions of Excitotoxicity: Excessive levels of extracellular neurotransmitters (NT's)
causing excitatory overstimulation and neuronal damage.
The fundamental process responsible for H-I damage of neurons is called excitotoxicity, a term
popularized in 1970s by John Olney that refers to cell death caused by excessive stimulation
of extracellular excitatory amino acid (EAAs) receptors (Choi &, Rothman, 1990). Both hypoxia
and ischemia result in the failure of energy-dependent ion pumps and causes cellular depo‐
larization, increasing the release of EAAs -glutamate and aspartate- into the extracellular space
in the cerebral cortex and basal ganglia.
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The amino acid glutamate is the major excitatory NTs in the central nervous system (CNS).
During neurotransmission, glutamate is released from pre-synpatic neurons by means of
depolarisation of the pre-synaptic neuronal endplate, and then diffuses across the synaptic
cleft to activate post-synaptic glutamatergic receptors. Several studies indicate that glutamate
receptor-mediated excitotoxicity is a key player in neuronal cell death and that it is more
critically involved in the developing brain than in the adult brain (Johnston, 2001). The
neuronal injury occurring with cerebral H-I has been attributed to overstimulation of the
Nmethyl-D-aspartate (NMDA) and alfa-amino-3-hydroxy- 5-methyl-4-isoxazole-propionic
acid (AMPA) subtypes of excitatory amino acid glutamate receptors. Acute energy deprivation
leads to the excessive release of extracellular glutamate and uncontrolled activation of
ionotrophic glutamate receptors NMDA, AMPA, and kainate, impedes energy-dependent
reuptake of glutamate and causes the rise in intracellular Ca2+ concentration. The massively
increased levels of intracellular second messenger Ca2+ trigger activation of toxic intracellular
pathways involving kinases, phosphatases, proteases, endonucleases, FRs, mitochondrial
dysfunction, inflammation, DNA damage, and, ultimately, irreversible neuronal injury and
death (Choi & Rothman, 1990; McDonald, 1998). Another important component of glutamate
synaptic dysfunction caused by H-I is postsynaptic neuronal membrane depolarization with
secondary opening of voltage-sensitive channels. Membrane depolarization due to high levels
of synaptic glutamate produces maximum channel opening and flooding of calcium and
sodium into neurons. Although high levels of glutamate can produce some degree of mem‐
brane depolarization under normal mitochondrial function, maximal excitotoxicity probably
occurs when there is synergism between high synaptic glutamate levels due to disruption of
glucose delivery and oxidative stress. The prominent role of the NMDA receptor–channel
complex in perinatal H-I is related in part to its special transient role in brain development.
The NMDA receptor subunits in the developing brain create populations of receptors that
input more calcium, open more easily and block less frequently than mature forms, allowing
them to serve these special developmental roles. However, this makes the immature brain
more susceptible to excitotoxic injury if critical levels of energy failure are exceeded. For
instance, neurotoxicity mediated by NMDA is more enhanced in the neonatal brain than the
adult brain. Besides, NMDA receptors play an important role in activity-dependent neuronal
plasticity during development Therefore, development-dependent changes in the expression
of NMDA receptor subunits and their composition are, at least in part, responsible for the fact
that immature brains are far more excitable and epileptogenic than the adult brain.
A second important mechanism for the destruction of ion pumps is the lipid peroxidation of
cell membranes, where enzyme systems, such as the Na+/K+-ATPase, are located. This leads to
water influx and cell swelling, causing cell death. EAAs also increase the local release of NO,
which may exacerbate neuronal damage, although its mechanisms are unclear. It is quite
possible that EAAs disrupt factors that normally control apoptosis, increasing the pace and
extent of programmed cell death. The regional differences in injury severity may be explained
by the fact that EAAs particularly affect the hippocampus, the developing oligodendroglia,
and the subplate neurons along the borders of the periventricular region in the developing
brain. This may be the basis for the disruption of long-term learning and memory faculties in
infants with HIE (Barks & Silverstein, 1992).
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4.2.3. Inflammatory mediators (Microglial and astrocyte activation)
Neuroinflammation, caused by activated microglia and astrocytes, plays a key role in the
pathogenesis of CP. Maternal intrauterine infection and inflammation are risk factors for the
development of PVL (characterized by focal necrosis around the ventricles, and diffuse
microglial and astrocyte activation in the immature WM) and CP in the neonate (Haynes et al,
2003; Leviton et al, 2010). The microglia -immune cells in the brain-, play an important role in
remodeling and growth during the fetal and postnatal periods, and they are proposed to be
involved in the pathophysiological mechanism for the development of CP in humans.
Activation of these cells can result in an exaggerated inflammatory response with formation
of FR, excitotoxic metabolites, and pro-inflammatory cytokines, leading to brain injury
(Dommergues et al, 2003; Li et al, 2008). In severe inflammation, astrocytes that normally
participate in the protection of neurons and in preventing oxidative injury, are unable to
maintain their neuroprotective role (Maragakis & Rothstein, 2006). H-I injury in the neonate
is progressive, producing lesions of variable severity including focal necrotic cell death, diffuse
WM injury, cystic or cavitary infarction and the resulting neuropathies linked to the activation
of neuroinflammatory processes (inflammatory cytokines, chemokines, and matrix metallo‐
proteinase (MMP) activity) that occur in response to the initial wave of cell death.
Cytokines may be classified as interleukins (IL), interferons, tumor necrosis factors, chemo‐
kines (proteins that stimulate leukocyte motility), and growth factors. Systemically, cytokines
may be ‘‘proinflammatory’’ (eg, IL-1b, TNFa, IL-6, IL-8) or ‘‘antiinflammatory’’ (eg, IL-4, IL-10,
TGFa). However, this subdivision may not apply to the CNS. Cytokines that are produced
peripherally can send signals to the brain, but more importantly, they are produced locally
within the CNS in response to acute insults, including H-I. Cytokines may act on neurons,
astrocytes, microglia, and endothelium, and may influence CNS injury indirectly by way of
systemic parameters, such as blood flow and temperature. Cytokines can also play trophic
roles during development, and their effects may differ depending on cell type (Grow & Barks,
2002). In experimental models, there is strong evidence that increased IL-1b gene expression
and bioactivity after HI contributes to the pathogenesis of H-I injury in the immature and adult
brain, (Hagberg et al, 1996). Clinical data also suggest that inflammatory mediators play a role
in the pathogenesis of H-I brain injury: In human infants, CSF IL-6 and IL-8 concentrations are
increased after birth asphyxia in comparison with controls; the magnitude of the increases
correlates with the severity of the encephalopathy (Savman et al, 1998).
Chemokines are cytokines that regulate leukocyte migration and activation. H-I induces
increased expression of two potent monocyte chemokines (MCP-1 and MIP-1a). This chemo‐
kine response precedes, and may mediate, the recruitment and activation of monocytes and
microglia. There is no direct evidence that these chemokines contribute to neonatal HI brain
injury. A large body of evidence implicates neutrophils and leukocyte adhesion molecules in
the pathogenesis of focal cerebral ischemia in the adult brain, but there is only limited
information to substantiate a role for these mediators in the pathogenesis of neonatal cerebral
H-I (Hudome et al, 1997).
Neural injury after H-I is exacerbated due to neuroinflammatory signaling from activated
microglia and peripheral infiltration of macrophage, cell death via necrotic and apoptotic
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mechanisms, and astrogliosis. Activation of microglia and macrophage infiltration is associ‐
ated with the necessary phagocytosis of cellular debris, but it also results in a burden of
increased production of neurotoxic substances, such as RNS and ROS, pro-inflammatory
cytokines, and the NMDA agonist quinolinic acid. Thus, prolonged activation of these
monocyte-derived cells for at least a week may elicit further deleterious changes in the brain
(Nakajima & Kohsaka, 2004).
4.3. Mechanisms of neuronal cell death after hypoxia-ischemia
Excitotoxic cell death occurs through necrosis and/or apoptosis (also known as programmed
cell death), the balance between modes of death may be influenced by the severity of the insult,
cell phenotype and location, and maturational stage. One important characteristic feature of
ischemia is selective neuronal necrosis (SNN), which is characterized predominantly by
neuronal death whereas the astroglial cells are spared, at least initially. Necrosis predominates
in more severely affected areas; apoptosis is seen more in penumbral areas of the injury. Several
important features distinguish apoptotic from necrotic death (Northington et al, 2001):
1. Apoptosis is a physiologic process. Is the mechanism for refining cell connections and
pathways during development by removing many neurons that will not be needed in
adulthood, it is an essential part of normal brain development. This fact may underlie the
observation that the propensity for experimental H-I to induce apoptosis peaks in the
early, postnatal period.
2. Apoptosis is an active process, dependent on activation of a family of proteases called
caspases that are modulated by other proteins (eg, those of the Bcl-2 family). The bio‐
chemical cascade of apoptosis can be blocked pharmacologically at several points.
3. Necrosis is characterized by cell swelling and eventual loss of cell membrane integrity
followed by cell lysis. Resultant inflammation is a significant part of necrotic death. In
contrast, apoptosis is an energy-dependent process and is characterized by a shrinking of
the cytoplasm, condensation of the nucleus and eventual fragmentation of the cell body
into smaller bodies. Markers of apoptosis such as cytoplasmic and nuclear condensation,
as well as nuclear DNA fragmentation, appear in neurones, particularly in the infarct and
penumbra of cerebral injury.
4. The time course of apoptotic death in H-I is slower than that of necrotic death. This feature
may provide a more prolonged window of opportunity for therapeutic intervention than
for necrotic death.
Early H-I-induced neuronal death occurs through necrosis (primary damage). Delayed
neuronal death (secondary damage) occurs hours or days later through a series of complex
and highly regulated biochemical and molecular events leading to apoptosis. Accumulating
data suggest that apoptosis plays a prominent role in the evolution of H-I injury in the neonatal
brain and may be more important than necrosis after injury. During neonatal brain injury,
excitotoxicity, oxidative stress, and inflammation all contribute to accelerated cell death by
means of either apoptosis or necrosis, depending on the region of the brain affected and the
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severity of the insult (Blaschke, 1996). This apoptosis–necrosis morphological continuum of
neuronal death after H-I is similar to that observed in neonatal rats after excitotoxic activation
of NMDA and non-NMDA glutamate receptors, suggesting that H-I neuronal injury is
triggered by the excitotoxic cascade (Portera-Cailliau, 1997; Martin, 1998; Bittigau, 1999).
Recent explosive progress toward dissecting the molecular basis of apoptosis revealed the
existence of family acting proteases, known as caspases. These protein-splitting enzymes act
in a cascade form when signals are transmitted from the various receptors. Caspases sequen‐
tially activate each other and several proapoptotic protein kinases and disable DNA repair
mechanisms (e.g., by cleaving poly (ADP-ribose) polymerase, PARP). Apoptosis can be elicited
through two pathways:
• Intrinsic pathway: in which translocation of cytochrome c from the mitochondria to the
cytoplasm is an early step; when translocated cytochrome c combines with ATP, apoptosis
protease activating factor-1 (Apaf-1) and procaspase-9, caspase-9 is cleaved to its active state.
• Extrinsic pathway initiated by cell membrane death receptor activation (e.g. TNF receptor).
Death receptor-ligand interactions lead to caspase-8 activation.
Activation of either caspase-8 or -9 (initiator caspases) leads to cleavage and activation of
caspase-3 (effector caspase). Caspase activation is modulated by the BCL-2 family of proteins,
which includes proapoptotic (eg, Bax) and antiapoptotic (eg, Bcl-XL) members. ROS can induce
apoptosis in neurons. This effect is mediated by mitochondrial cytochrome c release (Green,
2000). Current data implicate the caspase-9 pathway as predominant in acute neuronal injury.
Ca2+ is an important inducing agent in the mitochondria-dependent apoptotic pathway.
Increased free cytosolic Ca2+ may lead to uncoupling of mitochondrial oxidative phosphory‐
lation, inducing the mitochondrial the release of cytochrome c. Once released from mitochon‐
dria, cytochrome c specifically activates caspase 3, which triggers a biochemical cascade
involving activation of many other caspases and other substrates. Known substrates of
activated caspase-3 include PARP (a nuclear enzyme that participates in DNA repair), and
DNA-dependent kinase, endonucleases, and cytoskeletal proteins (eg, fodrins, actin, lamin).
Caspase-3 is strongly activated in animal models of H-I, resulting in increased activity of PARP
in neuronal nuclei, indicating activation of the DNA repair pathway (Mehmet, 1994). On the
other hand, pancaspase inhibitors are strongly neuroprotective when given several hours after
the insult (McDonald, 1997).
Severe cerebral ischemia also results in a major increase in intracellular Ca2+, which is closely
related to NO. Both play a fundamental role in signal transduction –controlling cell processes
such as proliferation (Ashkenazi, 1998). NO has several important physiologic functions in the
CNS. These include control of central and peripheral functions, modulation of synaptic
plasticity, perception of pain and neuronal damage, and protection. High NO levels may be
neurotoxic and induce apoptosis or necrosis. Changes in intracellular Ca2+ or NO may
alternatively lead to blockade or activation of the cell cycle, and the decision as to whether the
cell lives or dies is presumably a well-regulated phenomenon in which the duration and
intensity of the Ca2+ and NO signals may play a fundamental role. Identification of enzymes
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and substrates for these phosphorylation pathways would shed light on hypoxia-induced
processes leading to cell recovery or death (Esplugues. 2002).
NMDA channel overactivity, calcium entry into neurons, production of NO, and mitochon‐
drial dysfunction are intimately linked in a potentially lethal cycle. There is abundant evidence
that excitotoxic injury to neuronal mitochondria is linked to activation of neuronal death, and
mitochondria appear to play a central role in determining expression of injury as necrosis and/
or apoptosis, determining whether neurons live or die following hypoxic–ischemic insult. The
death receptor and mitochondrial apoptosis pathways converge at the caspases that cleave
multiple cellular substrates, ending in DNA fragmentation and cell death. It is noteworthy that
activation of apoptosis-executing caspases is much greater in the immature brain than in the
adult brain (Hu, 2000).
From the above it follows, that one of the main difficulties for developing a neuroprotective
pharmacotherapy is the existence of multiple cellular death mechanisms, occurring in different
cells or even in the same cell, which may all need to be inhibited. In fact, the widely accepted
apoptosis-necrosis dichotomy is being replaced by a more complex view involving a third type
of cell death, named autophagic cell death, characterized by the presence of intense autophagy
(Clarke, 2008). Whereas the roles of apoptosis and necrosis in such conditions have been
studied intensively, the implication of autophagic cell death has only recently been considered.
Autophagy is an essential pathway for the degradation and recycling of intracellular macro‐
molecules. The most important autophagic mechanism, macroautophagy, consists in the
sequestration of long-lived proteins and damaged organelles in multimembrane vesicles,
named autophagosomes, which then fuse with lysosomes to degrade their contents. Whereas
basal macroautophagy (called hereafter autophagy) plays a central physiological function in
maintaining cellular homeostasis, induced autophagy may have both survival and deleterious
roles. In neurons, autophagy has been demonstrated to be induced during development,
starvation, neurodegeneration, and also after different excitotoxic stimuli. More recently, an
involvement of enhanced autophagy in neuronal death following cerebral ischemia has been
proposed (Koike, 2008).
4.4. Neurogenetic and gliogenetic processes after H-I injury
Recent  studies  in  brains  damaged  by  H-I  insult  have  demonstrated  that  some  cellular
mechanisms can be activated in order to repair cerebral injuries. These mechanisms involve
the neural stem/progenitor cells (NSPs) normally resident in the subventricular zone (SVZ)
of the mammalian brain that can be stimulated by H-I to proliferate and differentiate into
both neurons and OLs. These new cells are likely to play an important role in repairing
neuronal and glial losses related to HIE. Perinatal H-I results in brain injury, whereas mild
hypoxic episodes result in preconditioning, which can significantly reduce the vulnerabili‐
ty of the brain to subsequent severe H-I. “In vivo”, hypoxic-preconditioning has been shown
to enhance cell survival and differentiation of progenitor cells in the CNS, stimulating SVZ
proliferation  and  neurogenesis.  This  phenomenon  may  be  a  positive  adaptation  for  an
efficient repair and plasticity in the event of a H-I insult (Ara, 2013). Therefore, the NSPs
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in the SVZ could be a valuable target for therapeutic strategies to enhance recovery after
cerebral H-I injury (Scafidi, 2008).
5. Therapeutic window
Brain injury following H-I insult is a complex process evolving over hours to days, which
provides a unique window of opportunity for neuroprotective treatment interventions. The
seminal concept emerging from both experimental and clinical studies is that brain cell death
does not necessarily occur during H-I (the ‘primary’ phase of injury), but rather that the
injurious event may precipitate a cascade of biochemical processes leading to delayed cell
death, hours or even days afterwards (the ‘secondary’ phase). Experimental studies in piglets,
immature rats, and fetal sheep have demonstrated the existence of both a primary phase of
energy failure during H-I, a ‘latent’ phase during which oxidative metabolism normalizes,
followed by secondary failure of oxidative metabolism. Consistent with these studies,
although with exceptions (some newborn infants exposed to profound asphyxia show no
initial recovery of oxidative metabolism after birth and typically have very severe brain injury
and high mortality), in many cases infants show initial, transient recovery of cerebral oxidative
metabolism followed by a secondary deterioration, with cerebral energy failure from 6 to 15
hours after birth. The severity of secondary energy failure correlates closely with the severity
of neurodevelopmental outcome at 1 and 4 years of age. Critically, for understanding labor
insults, experimental studies show that a single ‘sub-threshold’ insult that causes either minor
or no neural injury can lead to a phase of increased vulnerability to further insults in a similar
window of around 6 or more hours (Gunn, 2009). Advances in neuroimaging, brain monitoring
techniques, and tissue biomarkers have improved the ability to diagnose, monitor, and care
for newborn infants with neonatal encephalopathy, as well as to predict their outcome. The
importance given to the role of oxidative stress in newborn morbidity with respect to the higher
risk of FR damage in these babies is growing. However, challenges remain in early identifica‐
tion of infants at risk for neonatal encephalopathy, determination of timing and extent of H-I
brain injury, as well as optimal management and treatment duration (Buonocore, 2012).
The literature review reinforces the notion that the spectrum of H-I encephalopathy outcomes
represents a continuum, which has important implications for the prediction of outcome and
the indications for intervention. Perlman & Shah (Perlman & Shah, 2011) summarize predictive
clinical criteria at 3 time points: the first 6 hours of life, 6-72 hours of life, and at hospital
discharge. They highlight the predictions at pivotal decision making times: at 0-6 hours (the
earlier the better), to initiate or not to initiate neuroprotection, and at 6-72 hours, to identify,
implement, and achieve the goal of withdrawing lifesustaining therapy.
The “therapeutic window” is this interval after reperfusion (“reperfusion window”: narrow
therapeutic time-window within 6 hours of insult), during which an intervention might be
efficacious in reducing the severity of the ultimate brain damage. As we previously mentioned,
the cascade of biochemical and histopathological events initiated by H-I can extend from days
to weeks after the insult is triggered, which may provide a "therapeutic window of opportu‐
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nity", probably more extensive (ranging from 6 to 72 hours, called “cytoprotection window”),
for intervening in the pathogenesis of the developing brain. But such interventions are
currently limited by insufficient knowledge of the timing and duration of the so-called
therapeutic window in newborns (Barks, 2008; Levene, 2010). Recent data suggests that
interventions for perinatal HIE may be combined to enhance the protective and reparative
processes, and thought must be given to the best time to administer these interventions. As
we described before, injury evolves over long periods of time with different mechanistic
phases, adding to the already slow process of neuronal necrosis and apoptosis that can extend
for several hours to a day or more. Therefore, therapies will also need to be administered over
long periods of time, with different combination of drugs aimed at these temporally evolving
targets.
6. Neuroprotective therapies
Asphyxia thus constitutes one of the leading avoidable causes of morbi-mortality in the
newborn, and, therefore neuroprotection strategies oriented to prevent neuronal lesion (or at
least minimize its consequences) are currently one of the most important lines of research in
perinatal medicine. Before the introduction of neuroprotective therapies, the management of
neonates with HIE in Neonatal Intensive Care Unit (NICU), was limited to supportive
intensive care, including resuscitation in the delivery room followed by stabilization of
hemodynamic and pulmonary disturbances (hypotension, metabolic acidosis, and hypoven‐
tilation), correction of metabolic disturbances, (glucose, calcium, magnesium and electrolytes),
monitoring for multiorgan dysfunction and treatment of seizures.
There has been significant research progress in HIE over the last 2 decades, and many new
molecular mechanisms have been identified. Despite all these advances, therapeutic interven‐
tions are still limited. At present, magnesium sulfate in preterm- and hypothermia in term
newborns are currently the only treatments recognized as effective in neonatal HIE, and they
are the focus of completed or continuing clinical trials.
6.1. Hypothermia
Hypothermia has been shown to be neuroprotective at critical cellular and vascular sites of
cerebral injury in fetal/neonatal models of HI by inhibiting many steps in the excitotoxic-
oxidative cascade. The mechanism of action of hypothermia includes: 1) decrease in energy
use, decrease in cerebral oxygen consumption and amelioration of secondary energy failure;
2) inhibition of the increase of lactic acid in the brain; 3) reduction/suppression of extracellular
EAA –glutamate- accumulation; 4) inhibition of NOS activity and NO concentrations; 5)
suppression of FR activity and lipid peroxidation; 6) decrease of inflammation: inhibits platelet
activating factor (PAF); decreases the level of interleukin-1beta and the release of toxic
cytokines themicroglial/glial cells and inhibits protease activation, 7) attenuation of secondary
energy failure; 8) inhibition of mitochondrial failure; 9) inhibition of necrosis and decrease of
caspase-3 activation and morphologic evidence of apoptosis. Hypothermia has been shown to
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reduce cerebral metabolism, prevent edema and loss of membrane potential, decreas brain
energy use, prolong the latent phase, reduce infarct size, decrease neuronal cell loss, and the
extent of brain injury and epileptic activity, relieves the permeability of BBB and intracranial
pressure, helps to retains sensory motor function, and preserves hippocampal structures
(Shankaran, 2012).
Factors that influence the effects of hypothermia include the target body temperature, mode
of hypothermia induction (selective head cooling vs total body cooling), duration of hypo‐
thermia, and rate of rewarming. Hypothermia after neonatal HIE, to a target temperature of
33–34°C for 72 hours has currently been shown to reduce death or disability at 18 months or
increase the rate of survivors without disabilities. The safety and effectiveness of hypothermia
as neuroprotection agent has been reported in in many randomized controlled trials to date,
enrolling infants born at greater than or equal to 36 weeks or greater than or equal to 35 weeks
gestation, within the therapeutic window of 6 hours (Gluckman, 2005; Shankaran et al., 2005,
Shankaran et al., 2008; Azzopardi, 2009; Edwards, 2010; Rutherford, 2010; Zhou, 2010;
Simbruner, 2010; Jacobs, 2011; Tagin,2012).
These trials have all included moderate/severe stage of encephalopathy (Sarnat & Sarnat,
1976) as eligibility criteria in random assignment studies at < 6 hours of age. Three trials
included the additional criteria of abnormal amplitude-integrated electroencephalography
(aEEG).(Gluckman, 2005; Azzopardi 2009; Simbruner 2010).
The Cool Cap trial (Gluckman, 2005) involved 234 term infants with moderate or severe
encephalopathy and abnormal aEEG. Death or disability occurred in 66% conventional care
and 55% cooled group (adjusted odds ratio [OR] [95% CI] 0.61 [0.34–1.09], P 5.10). Predefined
subgroup analysis suggested that head cooling had no effect in infants with the most severe
aEEG changes but was beneficial in infants with less severe aEEG changes.
The National Institute of Child Health and Human Development (NICHD) Neonatal Research
Network (NRN) randomized controlled trial (RCT) of whole-body hypothermia for neonates
with HIE: 208 term infants with moderate or severe encephalopathy were randomly assigned
to whole-body cooling to an esophageal temperature of 33.5º C for 72 hours or usual care.
Death or severe disability occurred in 62% of the usual care group and 44% of the hypothermia
group (relative risk [RR] [95% CI] 0.72 [0.54–0.95], P 5.01) (Shankaran et al., 2005).
The Total Body Hypothermia for Neonatal Encephalopathy (TOBY) trial (Azzopardi, 2009)
enrolled 325 infants. Death or severe disability occurred in 53% of the standard care group and
45% of the hypothermia group (RR 0.86 [0.68–1.07], P 5.17). The rate of CP was lower, and
improved mental and psychomotor indices were noted in the hypothermia group as compared
with the usual care group (all P<.05). (Rutherford, 2010).
Hypothermia is currently the only treatment recognized as effective in neonatal HIE at present,
and the only recommends therapeutic as a standard practice (Biban, 2011). Hypothermia is
currently being recommended since 2010 by health care policy makers:
• The international Liaison Committee on Resuscitation (ILCOR). The most recent Interna‐
tional Consensus Conference was held in Dallas in February 2010 and the published
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conclusions and recommendations from this process form the basis of these 2010 ERC
Guidelines (guideline of ILCOR CoSTR 2010) (Hazinski, 2010).
• American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergen‐
cy Cardiovascular Care (Kattwinkel, 2010).
• The International Consensus on Cardiopulmonary Resuscitation and Emergency Cardio‐
vascular Care Science with Treatment Recommendations (Perlman, 2010).
• The 2010 guidelines released by the European Resuscitation Council (ERC) (Nolana, 2010).
• and the American Academy of Pediatrics (AAP) (Shelov, 2011).
The guides recommend therapeutic hypothermia as a standard practice for term or near term
infants with moderate to severe HIE, stating that during the postresuscitation period in greater
than or equal to 36-week gestation neonates with evolving moderate or severe encephalopathy,
hypothermia should be offered in the context of clearly defined protocols similar to published
trials. Further trials to determine the appropriate techniques of cooling, including refinement
of patient selection, duration of cooling and method of providing therapeutic hypothermia,
will refine our understanding of this intervention (Cochrane Database; Jacobs, 2013).
6.2. Neuroprotective drugs
Although therapeutic hypothermia is a significant advance in the developed world and
improves outcome, the rate of death or disability following hypothermia for neonatal HIE is
unacceptably high and ranges from 31% to 55% in the published trials, therefore it is becoming
evident that the association of moderate hypothermia with another neuroprotective interven‐
tions drugs may enhance the outcome.
Therefore, there still is an urgent need for other treatment options. Further, there are currently
no clinically established interventions that can be given antenatally to ameliorate brain injury
after fetal distress. One of the major limitations to progress is what may be called “the curse
of choice” (Robertson, 2012). A large number of possible neuroprotective therapies have shown
promise in pre-clinical studies (Painter, 1995; Kelen & Robertson, 2010). The lines of research
currently include: 1) antenatal therapy for fetuses with a diagnosis of antenatal fetal distress
at term; 2) and postnatal therapy of infants with moderate to severe neonatal encephalopathy.
To date, there is no consensus on which drugs have a higher chance of success in preventing
the continued neuronal loss for either antenatal or postnatal treatment in human neonates who
have suffered from HIE (reviewed in Degos, 2008; Gonzalez & Ferriero, 2008; Kelen &
Robertson, 2010; Rees et al, 2011; Buonocore et al, 2012; Robertson et al, 2012).
The majority of the drugs used as neuroprotective therapy in animal models does not penetrate
in good condition the BBB. Thus, drug delivery across the BBB to target cells to treat diffuse
brain injury is the hardest challenge. The development of new biocompatible dendrimers has
become an important objective for the companies involved in Biotechnology. Among the
potential applications of these nanopolymer biopharmaceuticals it would be improving the drug
transport to increase both the bioavailability and the active fraction, as well as the controlling
Neuroprotection in Perinatal Hypoxic-Ischemic Encephalopathy — Pharmacologic Combination Therapy
http://dx.doi.org/10.5772/57459
143
the release of pharmaceuticals in order to custom and /or prolong the drug delivery over time.
In this way, the use of nanoparticles opens a new door to cerebral HIE treatment.
Bellow, we review the drugs that have shown both higher neuroprotection and clinical safety
and, therefore, could be applied to neonates. Since many of them have several mechanisms of
action, they have been classified according to their predominant effect (see FIGURE 2).
6.2.1. Anticonvulsant drugs
The developing brain has both a higher incidence of seizures in human and animal models,
and experiences seizures that can produce long-lasting consequences that are also stage-
dependent (Ben-Ari, 2006). Perinatal H-I brain injury is one of the most important causes of
epilepsy (Carrascosa et al, 1996), which occur in the majority (15–60%) of children with CP.
Epilepsy is a disorder in which the balance between cerebral excitability and inhibition is
tipped towards uncontrolled excitability. Selected neuronal circuits as well as certain popula‐
tions of glial cells die from the excitotoxicity triggered by HI. The presence of seizure, practi‐
cally occurring within the first hours, predicates a poor outcome of HIE.
The treatment of seizures is an essential component of the HIE management. Seizures are
generally self-limited to the first days of life but may significantly compromise other body
functions, such as maintenance of ventilation, oxygenation, and blood pressure. Additionally,
seizures should be treated early and be well controlled, since even asymptomatic seizures (seen
only on the EEG) may continue to injure the brain. The energy metabolism can be compromised
by the hyperactive neurons, and both acute energy deprivation after HI insult and seizures are
implicated in excitotoxicity. Thus, the therapeutic value of antiepileptic drugs (AEDs) may
include not only the control of seizure activity but also the potentiall benefit for the compro‐
mised cellular energy metabolism (Aicardi, 2008).
Basic and clinical studies indicate that seizures in neonates have long-term neurodevelop‐
mental and psychiatric consequences, highlighting the need for novel pharmacotherapeutics.
The two most common classes of AEDs are GABAA receptor agonists and NMDA receptor
antagonists. Currently, the first-line medical treatment for neonatal seizures is composed of
drugs that increase GABA receptor channel chloride currents, like barbiturate and benzodia‐
zepines (Calabresi et al, 2003).
• Phenobarbital (FDA-approved)
Phenobarbital (PB) increases GABA subtype A (GABAA)-receptor channel chloride currents.
It is also important to acknowledge that PB has multiple potential modes of action in addition
to anticonvulsant effects that could contribute to neuroprotection in this setting, including
reduced cerebral metabolic demand, antioxidant effects and decreased cerebral edema.
PB controls seizures in less than half of newborns (Painter et al, 1999). This reduced efficacy
of GABA-enhancing AEDs has been linked to neuronal chloride transport in the developing
brain. In the adult nervous system, due to low intracellular levels of Cl-, GABA inhibits most
neurons by activation of GABAARs, causing Cl- influx, membrane hyperpolarization, and
inhibition. In immature neurons, the Cl-exporting activity of KCC2 is lower than in mature
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neurons and in the context of NKCC1 expression, neuronal [Cl-]i is higher and GABAA reversal
potential (EGABA) is more depolarized. High levels of expression of the Na+-K+-2Cl- (NKCC1)
cotransporter in immature neurons cause the accumulation of intracellular chloride and,
therefore, a depolarized Cl- equilibrium potential. This results in the outward flux of Cl-
through GABA(A) channels, the opposite direction compared with mature neurons, in which
GABA(A) receptor activation is inhibitory because Cl- flows into the cell (for review see De
Cabo-de la Vega et al 2006). This outward flow of Cl- in neonatal neurons is excitatory and
contributes to a greater seizure propensity and poor electroencephalographic response to
GABAergic anticonvulsants such as PB and benzodiazepines (Khanna et al, 2013). It is also
intriguing to consider that recent insights regarding the impact of maturational changes in
neuronal chloride transporter expression on GABA receptor function may provide strategies
that could improve the neuroprotective efficacy of PB in the neonate. Specifically, blocking the
neonatal neuronal chloride transporter with bumetanide can augment the inhibitory activity
of GABA agonists such as PB (Costa et al, 2006).
On the other hand, recent research have found that administration of PB is potentially harmful
drug, associated with widespread apoptotic neurodegeneration throughout the brain when
administered to immature rodents during the period of the brain growth spurt (Bittigau et al,
2003). Compounds that may cause neuronal apoptosis in the developing brain include
antagonists of NMDA receptors (ketamine), agonists of GABAA receptors (barbiturates and
benzodiazepines), and sodium-channel blockers (phenytoin, valproate) (Olney et al, 2002).
Nevertheless, PB remains the preferred drug for the treatment of seizures in neonates with
HIE (Volpe, 2008; Slaughter et al 2013). It is still a controversial issue whether PB treatment
should be administered before the seizure attacks. In a small randomized trial, treatment of
infants with HIE with PB within 6 hours of birth resulted in a decrease in death or disability
at three years of age (Hall et al, 1998). At the present time, anticonvulsant therapy to term
infants in the immediate period following perinatal asphyxia cannot be recommended for
routine clinical practice, other than in the treatment of prolonged or frequent clinical seizures
(Evans et al, 2007).
In a neonatal rodent model the early post- H-I administration of PB may augment the neuro‐
protective efficacy of therapeutic hypothermia (Barks et al, 2012). Sarkar et al. (Sarkar et al,
2012) found that the PB treatment before cooling did not improve the composite outcome of
neonatal death or the presence of an abnormal post-hypothermia brain MRI. Whether this
combination treatment could also result in improved neuroprotective efficacy in conjunction
with cooling is an interesting question for future research.
• Bumetanide (FDA-approved)
Low concentrations of the diuretic bumetanide have been shown to alter the ion gradient that
underlies the excitatory effects of GABA. Blocking the NKCC1 transporter with bumetanide
prevents outward Cl- flux and causes a more negative GABA equilibrium potential in
immature neurons. While several studies have reported anti-convulsant effects of bumetanide
(Kahle et al, 2009), others have found no significant anti-convulsant effect. The alteration of Cl-
transport by bumetanide reduces electrographic seizures, and the combination of bumetanide
Neuroprotection in Perinatal Hypoxic-Ischemic Encephalopathy — Pharmacologic Combination Therapy
http://dx.doi.org/10.5772/57459
145
and PB is significantly more effective than PB alone on seizure occurrence, frequency, and
duration (Dzhala et al, 2008). Currently there are two clinical trials evaluating bumetanide as
a treatment for neonatal seizures. A phase I trial (NCT00830531) is actively enrolling patients
in a randomized, double-blind, controlled dose-escalation study of bumetanide as an add-on
therapy to treat refractory seizures caused by HIE. A second trial (NCT01434225) is being
performed by a large, multi-center European group in an “open-label,” dose escalation fashion
to assess the effect of bumetanide in addition to PB for the treatment of neonatal seizures caused
by HIE. Data from these pilot studies will be utilized to guide the design of larger Phase III
trials that will determine the efficacy of bumetanide in the treatment of neonatal seizures
(Khanna et al, 2013).
6.2.2. Anti-calcium drugs: Calcium channel blockers
Calcium channel blockers such as Nimodipine, Flunarizine and Nicardipine.
Calcium antagonist pretreatment attenuates HI damage in immature animals models.
However, there is no clinical evidence, that such agents are neuroprotective in asphyxiated
newborn infants. This may be attributable to lack of selectivity of the available drugs for
neuronal calcium channels, poor BBB penetration, or the inability of these agents to affect
intracellular calcium stores. Besides, the use of calcium channel blockers in severely asphyxi‐
ated newborn infants has been associated with clinically important hypotension and fall in
cerebral blood-flow velocity, and if there is no cerebral autoregulation, may cause further
cerebral hypoperfusion (Levene et al, 1990).
6.2.3. Antiexcitatory drugs: Glutamate antagonists
Glutamate antagonists are the most studied neuroprotective agents.
A. Inhibition of glutamate release:
• Adenosine A2A receptor antagonist including clonidine and dexmedetomidine (FDA-
approved):  have  been  show  to  have  neuroprotective  potential  in  animal  models  of
perinatal H-I. Adenosine acts as a NTs in the brain through the activation of four specific
G-protein-coupled receptors (the A1, A2A, A2B, and A3 receptors). The A1 receptor has
long been known to mediate neuroprotection, mostly by blockade of Ca2+ influx, which
results  in  inhibition  of  glutamate  release  and  reduction  of  its  excitatory  effects  at  a
postsynaptic  level.  However,  the  development  of  selective  A1 and A2 receptors  ago‐
nists as anti-ischemic agents has been hampered by their major cardiovascular side effects
(Abbracchio & Cattabeni, 1999).
• Riluzole (FDA-approved): a 2-aminobenzothiazole, is a drug inhibiting glutamate reléase,
neuronal excitability, and interferes with the effects of proteins activated upon NMDA-
receptor stimulation. After discovery of its neuroprotective effects in 1994, riluzole was
approved by the FDA for amyotrophic lateral sclerosis (ALS). However, animal experimen‐
tation showed that modest neuronal losses in a H-I model evoked by excitotoxicity have a
severe impact on locomotor network function, and that they cannot be satisfactorily blocked
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by strong neurodepression with riluzole, suggesting the need for more effective pharma‐
cological approaches (Sámano et al, 2012).
B. The blockers of glutamate receptors:
The blockers of glutamate receptors [non-nmda (particularly AMPA receptors) and NMDA
receptors], have conflicting results. Antagonists of the NMDA receptors (NMDARs) for
glutamate are potent neuroprotective agents in several animal models of perinatal brain
lesions. Administration of pharmacologic antagonists of the NMDA, AMPA/kainate or
metabotropic receptors attenuates H-I-induced neuronal injury. Administration of an AMPA/
kainate antagonist (but not NMDA antagonists) attenuates H-I oligodendroglial injury (Follett
et al, 2000). Conversely, increasing the expression of glutamate transporters has been shown
to be neuroprotective in “in vitro” models of ischemic damage and an “in vivo” model of
amyotrophic lateral sclerosis. Collectively, these data indicate a neuroprotective role of
astrocytes by glutamate uptake via their glutamate transporters. Combination therapy with
non-NMDA and NMDA antagonists could achieve a dual beneficial.
• AMPA/kainate antagonist:
Topiramate (FDA-approved)
Topiramate (TPM) is a novel anticonvulsant agent currently used in adults and children older
than 2-yr-of-age, characterized by good absorption, high bioavailability, and good tolerability
(Elterman et al, 1999). TPM has multiple mechanisms of action, including: blocking sodium
channels, high voltage-activated calcium currents, enhancing GABAinduced influx of chlor‐
ide, and inhibiting kainate/ AMPA glutamate receptors; but also blockade of carbonic anhy‐
drase isoenzymes, and mitochondrial permeability transition pore). TPM blockade of AMPA
and kainate receptors (glutamate receptors non-NMDA) shows little neurotoxicity, although
their effects on other stages of brain development such as synaptogenesis have not been
evaluated, prevention of excitotoxicity with TPM appears to be a particularly promising
approach, since the agents shown to be effective experimentally are likely to be clinically safe,
at least in developing animals (Glier et al, 2004). TPM protected pre-OL against excitotoxic or
H-I death (Follett et al, 2004), a key event in the pathophysiology of WM lesions in preterm
infants, and protected the PVWM against damage induced by an AMPA-kainate agonist in
newborn mice (Sfaello et al, 2005). Subsequent studies that demonstrated that TPM treatment
alone confers neuroprotection on H-I brain injury in neonatal rats, with more prolonged
treatment (4 doses over 48h). It is more likely that greater neuroprotective efficacy is attribut‐
able to intrinsic AMPA-antagonist properties (Noh et al, 2006). TPM exert neuroprotective
effects against PVL (Follett et al, 2004).
In clinicals models no adverse effects attributable to TPM were detected (Filippi et al, 2010).
Filippi et al. (Filippi et al, 2012) are doing a project (three-centre phase II pilot study entitled
“Safety and Efficacy of Topiramate in Neonates With Hypoxic Ischemic Encephalopathy
Treated With Hypothermia (NeoNATI)”) to evaluate whether the efficacy of moderate
hypothermia can be increased by concomitant topiramate treatment, at 10 mg/kg once a day
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for the first 3 days of life. Any favourable results from this research might open new perspec‐
tives about the reduction of cerebral damage in asphyxiated newborns.
• Blockade of NMDA receptors:
NMDA receptors play key roles in successive steps of brain development, including the
proliferation, migration, survival, and differentiation of neurons (Lujan et al, 2005). Therefore,
blocking NMDA receptors at specific neurodevelopmental stages might adversely affect brain
development. Thus, in rats studied during the postnatal growth spurt, transient NMDA-
receptor blockade with the potent noncompetitive antagonist MK-801 led to massive cell death
by apoptosis (Ikonomidou et al, 2002). These findings constitute a strong argument against the
prolonged use of potent NMDA receptor antagonists during brain development.
Although glutamate receptor antagonists have shown excellent neuroprotective effects in
animal studies (Lippman-Bell et al, 2013), these effects have not been validated in clinical
studies. These agents all cause a similar spectrum of neuropsychological symptoms, and
several have important cardiovascular effects. As a result, studies of several NMDA antago‐
nists- Selfotel (CGS19755), Gavestinel, Eliprodil and Aptiganel (Cerestat, CNS 1102) - have
been halted; Dextrorphan is not efficacious and may be harmful at higher doses (Labiche &
Grotta, 2004; Jaffer et al, 2011). Other drugs that may interfere with glutamatergic neurotrans‐
mission include Amantadine and Memantine, two NMDA receptor antagonists devoid of the
psychotomimetic and neurotoxic effects of phencyclidine (PCP) or dizocilpine (MK-801) when
administered to adults. These drugs are neuroprotective in adults with conditions closely
related to excitotoxicity. Unlike MK-801 and other NMDA blockers, memantine also appears
to be relatively safe in the developing rat brain (Manning et al, 2010); their efficacy and safety
in newborns need to be determined.
C. Other modulatory sites on the NMDA receptor complex:
• Magnesium sulphate (FDA-approved)
Magnesium is a nonspecific competitive blocker of calcium channel and plays many important
roles in maintaining body homeostasis. Magnesium is involved in multiple physiological
processes that may be relevant to cerebral ischaemia, including antagonism of glutamate
release, NMDA receptor blockade, calcium channel antagonism, maintenance of CBF, cell
membrane permeability, mitochondrial functions, the ionic membrane current in conducting
cells. Prehypoxic treatment of magnesium sulfate ameliorates the severity of brain damage,
but posthypoxic treatment deteriorates it. This deleterious effect may be attributable to
hypotension caused by high-dose magnesium sulfate, which further worsens cerebral
perfusion (Sameshima et al, 1999).
Use of antenatal magnesium sulphate (MgSO4) for fetal neuroprotection of the preterm
infant: MgSO4 has been used for decades in pregnant women for different indications (to
obtain tocolysis and to treat eclampsia), with no reported adverse effects in the neonates.
MgSO4 was neuroprotective in a model of neonatal WM damage. In a retrospective case
control study, preterm infants exposed to antenatal magnesium sulfate were found to have a
reduced risk of developing cystic PVL (FineSmith et al, 1997). It has been shown to be effective
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for neuroprophalxis to decrease the risk of moderate to severe CP. The first multicenter
controlled clinical trial, where mothers at risk of delivering before 30 weeks of gestation were
given magnesium, was completed in 2003 by the Australasian Collaborative Trial of Magne‐
sium Sulphate (ACTOMg SO4) Collaborative Group (Crowther et al, 2003). Significant
perinatal side effects occurred, and neurodevelopmental benefits were noted in survivors
examined at 2-yr-of-age: substantial gross motor dysfunction (3.4% vs 6.6%; RR, 0.51; 95% CI,
0.29-0.91) and combined death or substantial gross motor dysfunction (17.0% vs 22.7%; RR,
0.75; 95% CI, 0.59-0.96) were significantly reduced in the magnesium group. No serious
harmful effects were seen. Cochrane Systematic Review has confirmed this effect (Doyle et al,
2009), the review concludes that antenatal magnesium sulphate therapy given to women at
risk of preterm birth substantially reduced the risk of CP in their children. Clinical practice
guidelines on Magnesium Sulphate prior to preterm birth for neuroprotection have been
developed in Australia (Clinical Practice Guidelines on Magnesium, 2011) and Canada (Magee
et al, 2011) by the Societies of Obstetricians and Gynaecologists; and lately, by the American
College of Obstetricians and Gynecologists and the Society for Maternal-Fetal Medicine
(Committee opinion, 2013).
Postnatal therapy: In a randomised controlled trial performed by the “Intravenous Magnesi‐
um Efficacy in Stroke (IMAGES) Study” investigators (Muir et al, 2004), a mortality slightly
higher in the magnesium-treated group than in the placebo group was shown, and did not
reduce the chances of death or disability significantly. Magnesium also has a number of
vascular effects, being that it inhibits NOS in a non-selective form, which in the case of eNOS
would be harmful; therefore its use in postnatal therapy of infants with neonatal encephalop‐
athy would be contraindicated.
• Xenon (Not FDA Approved)
Medical gases are pharmaceutical molecules which offer solutions to a wide array of medical
needs. More specifically however, gases such as oxygen, helium, xenon, and hydrogen have
recently come under increased exploration for their potential theraputic use with various brain
disease states including H-I, cerebral hemorrhages, and traumatic brain injuries. A colorless,
heavy, odorless noble gas, xenon has been of particular interest to researchers because of its
possible neuroprotective properties (Dingley et al, 2006). Since the discovery of xenon as an
NMDA receptor antagonist, there has been growing interest in its potential use as a neuro‐
protectant. Some of the features of xenon that specifically interest scientists and researchers
include its rapid introduction into the brain, favorable hemodynamic profile with little or no
toxicity, as well as its inability to be be metabolized (Liu et al, 2011). Xenon induces anesthesia
and exerts its analgesic actions by inhibiting the NMDA receptor signaling pathway. Addi‐
tional studies have demonstrated that xenon may act on the secondary messenger signaling
pathway via increases in cyclic guanosine monophosphate. Xenon’s role in antiapoptotic
mechanisms also demonstrates its neuroprotective qualities. Furthermore, Xenon plays an
important role in the anti-inflammatory process. Xenon can influence mechanisms regulating
the Ca2+ release channel on plasma membranes (inhibits plasma membrane calcium ATPase
pump activity), resulting in an increase in neuronal Ca2+ concentration and an altered
excitability in these cells.
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Researchers have also explored the possibility of using Xenon in combination with other
therapeutic strategies to evaluate its possible synergistic neuroprotective capabilities; Xenon
may offer haemodynamic benefits in clinical neuroprotection studies (Chakkarapani et al, 2012).
6.2.4. Antioxidative drugs
The neonatal brain has a high rate of oxygen consumption and low concentration of antioxi‐
dants, making it susceptible to damage. In humans, mature OL carry increased antioxidant
enzymes compared with the pre-OL present in the immature brain, which may partially
explain the susceptibility of premature infants to WM damage (Haynes et al, 2005). In an effort
to reduce oxidative damage to the neonate, a number of protective interventions have been
used, including (1) FR reducers, (2) ROS scavengers: antioxidant enzymes, and FRs nonenzy‐
matic scavengers, (3) lipid peroxidation inhibitors, and (4) NOS inhibitors. Antioxidant
strategies have been used successfully to diminish ischemic cerebral tissue damage in animals,
but the utility of a pharmacological agent as a clinically relevant therapeutic strategy may
depend, in part, on its ability to cross the BBB, since although ischemic injury disrupts the
integrity of the BBB, this disruption is by no means complete.
A. FR reducers:
• Deferoxamine (DFO) - FDA-approved-. The free iron induces the formation of ROS, and
exogenous iron significantly exacerbates excitotoxic and aggravates cystic PLV in newborn
mice (Dommergues et al, 1998). DFO is an iron chelator that decreases FR production by
binding with iron and decreasing the production of OH-. DFO is protective during exposure
to H2O2 or excitotoxicity “in vitro”, and in animal models of H-I (Sarco et al, 2000).
• Polyphenols
Resveratrol (Res) -(FDA)-approved- could be a prophylactic factor in the prevention of
ischemia/reperfusion ( I/R) injury, they attenuates I/R injury in cardiomyocytes by preventing
cell apoptosis, decreasing LDH release and increasing ATPase activity. NO, cGMP, PKC and
K (ATP) may play an important role in the protective role of Res. Moreover, Res enhances the
capacity of anti-oxygen FR and alleviates intracellular calcium overload in cardiomyocytes
(Shen et al, 2012).
• Allopurinol (FDA Approved)
The xanthine-oxidase inhibitor allopurinol (ALLO) reduces FR formation, thereby limiting the
amount of I/R damage. Hypoxanthine accumulates in the ischemic brain, and with reperfusion
is oxidized to uric acid and superoxide. Elevated uric acid concentrations in the first postnatal
day identify a subset of premature infants who are at high risk for having subsequent hemor‐
rhagic or ischemic injury (Perlman et al, 1998). Furthermore, ALLO also has a non-protein
bound iron (pro-radical) chelating and direct FR (hydroxyl) scavenging effect. Animal research
in asphyxiated pigs demonstrated beneficial effects of postnatally administrated ALLO on
cerebral energy status and cytotoxic oedema (Peeters-Scholte et al, 2003). Treatment with
ALLO reduces FR production following ischaemia and it reduces tissue injury in “in vitro”,
and high doses (50-200 mglkg) of ALLO effects cerebral protection in animal experiments and
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also exerts benefits on reduction of cerebral edema and neuropathological damage after
neonatal HIE (Palmer et al, 1993). In humans, the first work on the neuroprotective effect of
allopurinol was carried out by Russell and Cooke (Russell & Cooke, 1995), in a randomized
controlled trial of allopurinol prophylaxis in very preterm infants ( between 24 and 32 weeks
of gestation). In this trial of prophylactic ALLO for the prevention of PVL in preterm babies,
no protective effect was apparent. A prospective randomized study in human neonates,
examining the effects of ALLO in term asphyxiated neonates, showed an improvement of
electrocortical brain activity and a reduction in FR formation after neonatal ALLO adminis‐
tration (Van Bel et al, 1998). A more recent paper by Gunes et al (Gunes et al, 2007) reports an
improved neurological outcome after postnatal ALLO administration (40 mg/kg/day, 3 days,
within 2 hours after birth) compared to a placebo in term asphyxiated neonates. Benders et al
(Benders et al, 2006), however demonstrated that ALLO was not effective if administrated 3
to 4 hours after the hypoxic incident to severely asphyxiated neonates. However, when the
most severely asphyxiated children were excluded from the study, a beneficial effect of ALLO
was seen on neurological development. Apparently, no advantage of neonatal treatment is
seen anymore when the interval to the initiation of treatment is too long or when the brain
damage is too severe. This has probably been the major disadvantage of late postneonatal
treatment with ALLO on the NICU. ALLO administrated at the NICU is likely to be given too
late to provide adequate neuroprotection during the early period of reoxygenation in which
the vast amount of FR is being produced. Apparently, when the asphyxia has been too severe,
the inflicted brain damage can no longer be reversed. It is conceivable that earlier ALLO
treatment, i.e. the use of ALLO during labour in case of suspected foetal hypoxia, provides the
opportunity to start earlier with the treatment, thereby limiting the amount of I/R injury and
improving neurological outcome. Animal and human studies suggest that administration of
ALLO immediately prior to delivery in case of suspected foetal asphyxia might reduce HIE.
In a study in the chronically instrumented foetal sheep, they were able to show evidence of
cardio-and neuroprotection after antenatal ALLO administration to the pregnant ewe during
repeated periods of ischaemia (Derkset al, 2006). Maternal administration of ALLO has been
proposed as prebirth treatment when there is suspicion of an adverse event eliciting perinatal
asphyxia. A prospective randomized placebo controlled pilot study, in which they adminis‐
tered ALLO to the pregnant woman when foetal asphyxia was imminent, showed an inverse
correlation between the levels of ALLO and the amount of S100B, a biomarker for brain tissue
damage, in cord blood (Torrance et al, 2009). A clinical trial of antenatal allopurinol is in
progress (Kaandorp et al, 2010).
B. Antioxidant enzymes (Endogenous antioxidants):
SOD, GPX, and CAT, are considered the classical  antioxidant enzymes.  One therapeutic
approach for the destruction of oxygen FRs generated during and after H-I is the administra‐
tion of specific enzymes known to degrade highly reactive FR to a nonreactive component. SOD
and CAT are enzymes poorly soluble and with short half life, so that should be conjugated to
polyethylene glycol, which prolongs their circulatory half-life and facilitates penetration of the
BBB. Notwithstanding that, the latency time to initiate therapeutic effects is unacceptably long,
making them useful only as preventive. Because of their large molecular sizes, they are restricted
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to the vascular space. In newborn animals, neuroprotection has only been shown when these
agents have been administered several hours before the HI insult (Shimizu et al, 2003).
C. Free radical nonenzymatic scavengers:
• N-Acetylcysteine (NAC) (FDA Approved)
NAC is a precursor of glutathione and can therefore act as an anti-oxidant and is also a
scavenger of ROS. NAC is used clinically for mucolysis and as an antidote for paracetamol
intoxication in high doses. It also reduced oxidative stress, inflammation, and minimized H-
I-induced brain injury in various acute models. In addition to reducing total tissue loss, NAC
reduced WM injury, prevented endotoxin-induced degeneration of OL progenitors and
hypomyelination in developing rat brain (Paintlia et al, 2004). The mechanism of NAC
neuroprotection appears to be related to reduced oxidative stress, preservation of the scav‐
engers GSH and Trx2, attenuated activation of apoptotic proteases (caspase-3, calpain), and
reduced inflammation. The protective effect of NAC was much more pronounced than that
produced by another FR scavenger, melatonin, when administrated before and after lipopo‐
lysaccharide-sensitized H-I. NAC was also effective when administered directly after H-I
(three days after) (Wang et al, 2007).
NAC is transported across the placenta and it is considered safe during pregnancy. Therefore,
although transport across the BBB is believed to be poor, it has been assumed that NAC has
potential therapeutic value in humans, performing its neuroprotective action at the level of
the vascular bed (Schaper et al, 2002). NAC is associated with adverse reactions ranging from
nausea to death (most of the latter due to incorrect dosing) which limits its use in humans.
(Sandilands & Bateman, 2009; Knudsen et al, 2005).
NAC is the most effective therapy for acetaminophen (APAP) toxicity and is currently
available for children for oral and intravenous (IV) administration; both routes are equally
effective and safe (Green et al, 2013). Currently, there are three protocols that are used in
acetaminomiphen ingestion:
72-hour oral-NAC: 140 mg/kg of oral NAC followed by 70 mg/kg every 4 hours for an
additional 17 doses.
20- hours IV-NAC: consists of a continuous IV infusion - 300 mg/kg- of NAC, patiens are given
a loading dose of 150 mg/kg over 15 minutes, followed by 50 mg/kg over 4 hours and then 100
mg/kg over the next 16 hours.
48-hours IV-NAC: consisted of a loading dose of 140 mg/kg followed by 12 doses of 70 mg/kg
every 4 hours.
The most frequently used protocol is the Simplified N-acetylcysteine dosing regimen -standard
preparation of IV-NAC 30 g in 1 L of 5% dextrose in water, with a 150-mg/kg loading dose
administered over 1 hour followed by an infusion of 14 mg/kg/h for 20 hours – this single
intravenous bag protocol is effective and well tolerated, and there is infrequent interruption
of therapy by dosing errors (Johnson et al, 2011). Both the IV and oral NAC have generally
mild adverse drug reactions. Nausea and vomiting have been the most common reported
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adverse events and were more common with oral treatment (9%). Anaphylactoid reactions
were more common with IV administration (2%). The changing between administration
routes, introducing deviations from “standard” treatment, may decrease these side effects
(Bebarta et al, 2010). In a medication error in prescribing paracetamol for closing a patent
ductus arteriosus in a preterm infant, NAC was indicated without showing adverse drug
reactions (Brener et al, 2013).
There is no consensus on a neuroprotective dose, and a wide range of concentrations have
been used in experimental studies. After neonatal I/R in piglets, NAC at doses of 150-mg/kg
bolus and 20 mg/kg/h, IV for 24 hours, reduced cerebral oxidative stress with improved
cerebral oxygen delivery and reduced caspase-3 and lipid hydroperoxide concentrations in
cortex (Liu et al, 2010). With smaller dosages (30 mg/kg bolus then 20 mg/kg/h infusion) in
newborn piglets with I/R, postresuscitation administration of NAC lowered cerebral lactate
levels, reduced cerebral oxidative stress (significantly attenuated the increase in cortical H2O2,
but not NO, concentration) and improved cerebral perfusion (Lee et al, 2008). Furthermore,
the anti-inflammatory effect reduced lung edema and neutrophil influx into the lung and
partly reversed surfactant dysfunction in the meconium aspiration syndrome model (Mokra
et al, 2013). Combination therapy of NAC and systemic hypothermia induced immediately
after neonatal H-I improves infarct volume, and reduced both white and grey matter damage
after focal HI injury injury in neonatal rats (Jatana et al, 2006). By contrast, Olsson et al (Olsson
et al, 1998), report that free NAC at 100 mg/kg showed some efficacy in attenuating inflam‐
mation and oxidative injury in the brain, but the improvement did not translate into myeli‐
nation, neuronal counts or motor function in CP. The only randomized clinical trial in preterm
newborns demonstrated that continuous infusion of NAC for 6 days after birth did not
improve the incidence of chronic lung disease but did appear to reduce the incidence of PVL
(Ahola et al, 2003).
Dendrimer-based N-acetyl-l-cysteine (D-NAC): Dendrimers are a nanopolymer biopharma‐
ceutical emerging as potential intracellular drug delivery vehicles. The efficacy of the activity
“in vitro” of anionic polyamidoamine (PAMAM-COOH) dendrimer-N-acetyl cysteine
(DNAC) was significant, even at the lowest dose, and its activity compared to free NAC
increase 16x higher dosage (Wang et al, 2009). The bioavailability “in vivo” of free NAC is poor
(the terminal half-life was 5.58 h after IV administration and 6.25 h after oral administration.
Oral bioavailability of total NAC was 9.1%). However, IV administration of a single 10 mg/kg
dose of D-NAC resulted in a significant improvement in neuronal injury and motor function
in CP kits. Moreover, the improvements seen with NAC-100 were similar to that seen with D-
NAC at 1% of the dose improved uptake and efficacy of D-NAC when compared to free NAC
in activated microglia, as shown previously “in vitro”, delivery of a higher drug-payload to
the target cells (activated microglia and astrocytes) by the dendrimer “in vivo”, and decreased
toxicity of the drug for neurons when conjugated with the dendrimer. The effectiveness of the
D-NAC treatment, administered in the postnatal period for a prenatal insult, suggests a
window of opportunity for treatment of CP in humans after birth (Kannan et al, 2012). The
nanoparticles D-NAC open a new door to cerebral palsy treatment (Crunkhorn, 2012; Andón
et al, 2012).
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• Melatonin (FDA Approved)
Melatonin is an indoleamine that is formed in higher quantities in the adult. It is produced
mainly by the pineal gland and is a naturally occurring hormone that binds to specific receptors
and allows the entrainment of circadian rhythms in several biological functions. But it can also
function as neuroprotective antioxidant (as a direct scavenger of ROS and NO), and has anti-
apoptotic effects. Because of its lipophilic properties, melatonin easily crosses most biological
cell membranes, including the placenta and the BBB. Several animal studies have shown
neuroprotective benefits from melatonin treatment, both when given before and after birth. It
has been found to provide long-lasting neuroprotection in experimental H-I and focal cerebral
ischemic injury. Melatonin may exert some of its protection on developing WM in H-I sheep
model via an anti-microglial effect (Welin et al, 2007). Newborns treated with melatonin were
also found to have decreased proinflammatory cytokines (Gitto et al, 2004 and 2005).
Clinically, melatonin has been used safely in children with sleep abnormalities related to
neurological disease (Jan & O’Donnell, 1996) and in septic newborns (Gitto et al, 2001) without
serious adverse effects. Melatonin appears to have beneficial effects when given to asphyxiated
newborns. It was shown to significantly reduce plasma levels of malondialdehyde and nitrate/
nitrite, two robust indicators of oxidative stress (Fulia et al, 2005). In a small clinical trial,
melatonin was given orally to newborn babies who had suffered birth asphyxia. In terms of
mortality, 3 out of 10 asphyxiated babies died in the vehicle treated group, whereas there were
no deaths in the post-asphyxia babies treated with melatonin. Importantly, this study did not
report any adverse effects arising from the melatonin treatment, and clinical use of melatonin
in the neonatal period has now been proposed (Gitto et al, 2009).
The optimal neuroprotective dose still needs to be determined, although Robertson et al
(Robertson et al, 2013), in a piglet model of perinatal asphyxia, demonstrate that the therapeutic
hypothermia plus IV melatonin (5 mg/kg/h) significantly reduced the H-I-induced. The safety
and improved neuroprotection of a potential treatment with a combination of melatonin and
cooling support the initiation of phase II clinical trials in infants with moderate and severe
neonatal encephalopathy.
• Tetrahydrobiopterin (FDA Approved)
BH4 is an important co-factor for a number of enzymes, such as aromatic amino acid hydrox‐
ylases, which converts phenylalanine into tyrosine (phenylketonuria), tyrosine into L-dopa,
and tryptophan into 5-hydroxytryptophan and NOS. BH4 may function as a FR, but it has also
been reported that inhibition of biopterin synthesis reduces ischemic brain damage (Kidd et
al, 2005). BH4 is a developmental factor determining the vulnerability of fetal brain to H-I.
There is evidence that BH4 deficiency can exacerbate oxidative injury (Madsen et al, 2003) and
that neonatal H-I can cause relative BH4 deficiency (Fabian et al, 2010). Fujioka H et al (Fujioka
et al, 2008) found neuronal iNOS expression and increase of NO production in the acute phase
of H-I in a newborn-piglet model, but brain biopterin did not increase despite plasma biopterin
five-fold elevation These findings suggest that the capacity of biopterin production in the CNS
is inferior to that in other organs in the acute phase of H-I. The BBB is thought to prevent the
transport of biopterin from the blood to the brain, therefore the initial shortage of biopterin in
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a H-I brain may affect the severity of brain damage. Maternal treatment with BH4 increased
fetal levels in basal ganglia and significantly ameliorated motor deficits and decreased
stillbirths (Vasquez-Vivar et al, 2009).
• Vitamin C (FDA Approved)
Ascorbic acid (AA, vitamin C) is an important enzyme cofactor and water-soluble reduc‐
ing agent that is highly concentrated in the adrenal gland and CNS. AA concentrations are
lowest in plasma (0.01–0.1 mM), intermediate in cerebrospinal and extracellular fluid (0.05–
0.5 mM) and highest in neuropil of the brain (1–3 mM). AA is a potent antioxidant, which
scavenges various types of ROS, and its neuroprotective effect has not been established yet.
Because vitamin C does not penetrate the BBB, therapeutic,  nonenzymatic scavenging of
FRs can be accomplished by AA only at very high physiological concentrations (Jackson et
al, 1998). Some studies have shown that AA has a neuroprotective effect; however, the issue
is still controversial. Since higher dose of AA may cause side effects such as oxaluria and
kidney stone (Massey et  al,  2005),  erythrocyte damage leading to hemolytic anemia and
hyperbilirubinemia in infant (Ballin et al, 1988), it might also have harmful effects on brain.
AA can act as pro-oxidant and cause neurotoxicity “in vitro” by reducing transition metal
ions  under  certain  conditions  (Buettneret  al,  1996).  Only  one  prospective,  randomized
double-blinded controlled clinical study in term infants with perinatal asphyxia has been
performed,  which  found  that  the  combination  of  AA  with  ibuprofen  had  no  effect  on
outcome at 6 months of age (Aly et al, 2009).
Although  the  antioxidant  vitamin  C  does  not  penetrate  the  BBB,  its  oxidized  form,
dehydroascorbic acid (DHA), enters the brain by means of facilitated transport. AA can be
oxidized to DHA in the stomach. Several studies demonstrated that AA and DHA have
neuroprotective effects  in adult  animal models of  HI.  IV DHA would improve outcome
after stroke because of its ability to cross the BBB and increase brain antioxidant levels. A
dose of 250 mg/kg or 500 mg/kg DHA administered at 3 hours post-ischemia reduced infarct
volume by 6- to 9-fold, to only 5% with the highest DHA dose (P <.05). Teratological and
adverse effects have not been documented (Huang et al,  2001). AA may be given to the
mothers  if  the  safety  of  its  use  is  established,  since  AA has  been reported to  cross  the
placental barrier (Rybakowski et al, 1995).
• Vitamin E (FDA Approved)
Vitamin E, a clinically safe agent, has been shown to be effective in cultured pre-OL models
(Back et al, 1998). Clinical trials in very preterm infants have been confined to vitamin E
for the prevention of IVH (Sinha et al, 1987). In rat pups, there was no benefit from postnatal
treatment after H-I with Mito vitamin E, a mitochondrial antioxidant (Covey et al, 2006).
However, in a study in asphyxiated rat pups, the combination of methylprednisolone with
vitamin E therapy reduced H-I brain damage significantly (Daneyemez et al, 1999). Nakai
et  al.  (Nakai  et  al,  2002)  reported  that  the  combined  administration  of  AA  and  alpha-
tocopherol  (vitamin E)  to pregnant rats  before transient  intrauterine ischemia was effec‐
tive against secondary mitochondrial dysfunction in the neonatal rat brain.
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D. Bioactive lipid mediators (Membrane “stabilizers”):
Considerable experimental evidence supports a pathogenetic role for lipid mediators in
perinatal H-I brain injury (Grow et al, 2002). Bioactive lipid mediators that may play a role in
cell signaling include arachidonic acid (AA), prostaglandins, leukotrienes, thromboxanes, and
PAF. Membrane phospholipids are hydrolyzed by phospholipase A2 (PLA2) to release FFA,
including AA, and lysophospholipid. Many studies have associated ROS-mediated damage
with a disturbance of cell membrane integrity and subsequent increase in intracellular Ca2+,
which, in turn, activate a number of Ca2+ dependent enzymes including PKC and PLA,
damaging membranes directly and initiating the production of lipid mediators, including AA
and PAF. H2O2 has been shown to cause AA release in numerous cell systems, including cells
in the CNS (Samanta et al, 1998). ROS produced during post I/R react with membrane
phospholipids to form oxidized lipids, some of which have PAF-like activity. High concen‐
trations of PAF or PAF-like oxidized lipids may contribute to neuronal injury by increasing
intracellular calcium concentrations, by stimulating production and release of pro-inflamma‐
tory mediators from neurons or microglia, or by upregulating cyclo-oxygenase-2 (COX-2).
Additionally, the involvements of different PLA2s, including cPLA2, iPLA2, and sPLA2, have
been implicated in the oxidative-mediated AA release process (Martinez et al, 2001). XU et al
(XU et al, 2003) showed that the response of astrocytes to oxidant compounds such as H2O2,
which stimulated signaling pathways leading to the activation of cPLA2 and iPLA2
(Ca2+independent) and the increase in AA reléase.
• Citicoline (FDA Approved)
Cytidine-5-diphosphocholine (CDP-choline as an endogenous compound that can also be
administered exogenously  as  citicoline)  is  an  endogenous  nucleoside  that  is  an  essential
intermediate  in the synthesis  of  phosphatidylcholine,  a  major  neuronal  membrane lipid.
Citicoline and its  hydrolysis  products (cytidine and choline)  play important roles in the
generation of phospholipids which are involved in membrane formation and repair, and it
is known to have neuroprotective effects. The mechanisms that may explain the neuropro‐
tective actions of citicoline include prevention of FFA release, stimulation of phosphatidyl‐
choline  synthesis,  preservation  of  cardiolipin  and  sphingomyelin  levels,  increase  of
glutathione  synthesis  and  glutathione  reductase  activity,  restoration  of  Na+/K+-ATPase
activity, and antiglutamatergic effects. The neuroprotective properties of CDP-choline seem
to be related on glutamate-mediated cell death (Adibhatla et al, 2002; Hurtado et al, 2005).
Citicoline  might  decrease  the  extracellular  level  of  glutamate  by  inhibition  of  neuronal
glutamate efflux and increased astrocytic glutamate uptake. It has been suggested that the
neuroprotective effect of this compound is related to inhibition of the glutamate induced
apoptotic pathway of cell injury (Mir et al, 2003). The protective effect of CDP-choline might
also  be  associated  with  its  actions  on  cell  membrane  stability  because  citicoline  has
distinctive  membrane-modulating  properties  (Secades  et  al,  2006).  Citicoline  decreases
phospholipase  A2  stimulation  and  hydroxyl  radical  generation  in  cerebral  ischemia
(Adibhatla et  al,  2003).  Lately,  it  has been suggested a possible contribution of the gene
PNPLA4, and codes for calcium-independent PLA2, as one of the mecanisms through which
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the citicoline may act (Carrascosa-Romero et al, 2012); and regulative effect on the expres‐
sion  of  intercellular  adhesion  molecule-1  (ICAM-1)  mRNA  in  neonatal  brain  with  H-I
damage (Miao et  al,  2005).  The upregulation of  the inflammatory genes and their  prod‐
ucts precedes leukocytes’ adhesion to endothelial cells and their migration into the ischemic
tissue, suggesting that these upregulated adhesion molecules on brain capillary endotheli‐
um play an important role in leukocyte migration into ischemic brain tissue (Wang et al,
1995).  “in vitro”,  Matyja et  al  (Matyja et  al,  2008) demonstrated that CDP-choline exerts
neuroprotection in progressive motor neurons injury in a model of chronic excitotoxicity.
It  inhibited  mainly  neuronal  apoptotic  changes,  whereas  necrotic  and  autophagocytic
abnormalities were not reduced. This confirms the suggestion that citicoline might protect
neurons against the glutamate-induced apoptotic pathway probably via a negative effect
on activation of the caspase cell death pathway (Mir et al, 2003); markedly reduced caspase-3
activation and Hsp70 expression 24 h after  the insult,  and dose-dependently  attenuated
brain damage in a rat model of birth asphyxia (Fiedorowicz et al,  2008).  Diederich et al
(Diederich et  al,  2012)  demonstrated that  citicoline  (100  mg/kg)  for  10  consecutive days
starting 24 hours after ischemia induction, have an extended therapeutic window.
In addition citicoline has convincingly been shown to also have neuroregenerative effects
although the underlying mechanisms are unknow. As a first mechanism contributing to this
more favorable neurological outcome, they could identify increased neurogenesis in the SVZ
and migration of neural progenitors to the lesion with increased neurogenesis also within the
peri-infarct area. A second component of the regeneration-enhancing effect of citicoline was a
shift toward excitation in the perilesional cortex (Diederich et al, 2012).
Citicoline has been shown to have neuroprotective effects in a variety of CNS injury models,
including focal and global cerebral ischemia (Trovarelli et al, 1981). In clinical trials, citicoline
administered after acute ischemic stroke in adults, improved neurological outcome with mild
adverse effects (Davalos et al, 2002; Labiche & Grotta, 2004; Saver, 2008). A recent drug
surveillance study on acute ischemic stroke in 4,191 patients (Cho and Kim, 2009) showed that
oral citicoline (500-4000 mg/day) administered within less than 24 h after acute ischemic stroke
improved neurological, functional and global outcomes without significant safety concerns.
By contrast, in a randomised, placebo-controlled study (ICTUS trial), citicoline, (1000 mg every
12 h IV during the first 3 days and orally thereafter for a total of 6 weeks) in patients with
moderate-to-severe acute ischaemic stroke, was not efficacious in the treatment of moderate-
to-severe acute ischaemic stroke (Dávalos et al, 2012). These differences could be due to dosage,
interaction with other drugs when they are administered simultaneously or to the fact that
necrosis phenomena are more marked than those of apoptosis. However, the apoptosis in the
newborn plays a prominent role in the development of H-I injury i and may be more important
than necrosis after injury. Additionally, the neurogenesis in the SVZ and migration of neural
progenitors are more marked in the newborn than in adults. CDP-Choline administration to
newborn infants (100 mg/kg/day, IV) was well tolerated without side effects (Valls et al, 1988;
Wang et al, 1997). In the context of the well-known excellent safety profile of citicoline, these
data suggest that success in the clinical evaluation of the efficacy of this drug in human neonatal
asphyxia may be warranted.
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• Edaravone (Not FDA Approved)
Edaravone, 3-methyl-1-phenyl-2-pyrazolin-5-one, (MCI-186) significantly decreased lipid
peroxidation (thiobarbituric acid reactive substance levels) of the damaged brain hemisphere
(Keda et al, 2002). Edaravone is a FR scavenger that improves the outcome after cerebral
ischemia in humans and is used for treatment after acute stroke (Group EAIS, 2003) and
traumatic brain injury (Itoh et al, 2009). Since edaravone has been approved in Japan for use
in patients with cerebral infarction, it could be a promising candidate for the treatment of
neonatal HIE.
E. nNOS inhibitors (Not FDA approved):
NO, a water-soluble, diffusible gas, has many physiological roles including regulation of
gastrointestinal  motility,  vasorelaxation,  and furthermore  performs an  important  role  in
synaptic  neurotransmission  (intercellular  messenger  and  signaling  molecule),  and  is
important for neuronal survival, differentiation, and precursor proliferation. NO can also
contribute to tissue injury, and has been shown to play a dichotomous regulatory role in
the brain; neuronal destruction and protection (Chen et al, 2004). NO prevents apoptosis
of  neuronal  cells  via  two  mechanisms;  first,  inhibition  of  caspase-3  activity  through  S-
nitrosylation of cysteine residues in the protease,  and second, cGMP-dependent (Lipton,
1995).  NOS catalyzes  the  synthesis  of  NO from the  conversion of  arginine  to  citrulline.
susceptibility to HI damage (Ferriero et al, 1996). Cerebral ischemia stimulates production
of NO by neurons and microglia.
NO is generated by three distinct nitric oxide synthases: neuronal (nNOS), endothelial (eNOS),
and inducible synthases (iNOS). Constitutively expressed nNOS and eNOS are activated by
increased intracellular calcium, by way of the NMDA receptor stimulates; nNOS plays a
physiologic role in excitatory neurotransmission; eNOS produces vascular smooth muscle
relaxation; iNOS is upregulated by hypoxia, cytokines, or endotoxin in monocyte /macro‐
phage/ microglia and is calcium independent; its induction can result in the production of large
quantities of NO (Moncada et al, 1991). Selective inhibition of nNOS or iNOS has shown
potential as a neuroprotective strategy, but nonspecific blockade of nNOS and eNOS is not
protective (Marks et al, 1996). During I/R, nNOS plays a role in NO production, but iNOS only
contributes to NO production during reperfusion.
Selective nNOS inhibitors:
The traditionally most employed nNOS inhibitor has been 7-nitroindazole (7-NI) (Muramatsu
et al, 2000), in adult stroke, protection by 7- NI has been inconclusive, this may reflect non-
specific inhibition of eNOS, causing a decrease in CBF (Willmot et al, 2005). At present, the
new inhibitors HJ619 and JI-8 are at least few hundred fold more specific than 7-NI; the new
compounds tested in a perinatal model of H-I, inhibited fetal brain NOS activity “in vivo”,
reduced NO concentration, and dramatically ameliorated the number of deaths and CP in a
rabbit model (Ji et al, 2009). These compounds are water-soluble and can be given IV. The
starting dose is unknown. Adverse effects are also unknown (Robertson et al, 2012).
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• Iminobiotin (Not FDA approved)
2-iminobiotin, a dual inhibitor with combined inhibition of nNOS and iNOS. Iminobiotin
exhibits neuroprotective effects in rats following H-I (van den Tweel et al, 2005), showed
protection only in female rat pups after H-I, but the protection was independent of the NO
pathway (Nijboer et al, 2007). Orphan designation (EU/3/09/701) was granted by the European
Commission to Neurophyxia for 2-iminobiotin for treatment of perinatal asphyxia on the basis
of potential activity. At the time of submission of the application for orphan designation, no
clinical trials with the designated product in patients with perinatal asphysia had been started
and 2-iminobiotin was not authorised anywhere in the EU for perinatal asphyxia.
6.2.5. Anti-inflammatory drugs
The CNS has its own resident immune system, in which glial cells (microglia, astrocytes, and
OL) not only serve supportive and nutritive roles for neurons but also engage from time in
several "inflammatory" processes that defend the CNS from pathogens and help it to recover
from stress and injury. Cytokines and activated microglia/macrophages may extend neuronal
injury and/or sensitize the developing brain to a second insult. Therefore, interference with
their effects would be expected to reduce subsequent neurological deficits. However, cytokines
such as IL-1 β or IL-6 were found to exert trophic effects on neurons, at least in cell cultures
(Otten et al, 2000). Similarly, activated microglia/macrophages, in addition to exerting toxic
effects, can display protective properties, such as scavenging of excess glutamate through
increased expression of glutamate transporters (Vallat-Decouvelaere et al, 2003).
Accumulating evidence suggests that targeting delayed neuroinflammatory mechanisms may
be a promising avenue for therapeutic intervention (Leonardo & Pennypacker, 2012). Anti-
inflammatory interventions have shown promise in experimental models of combined gray
and white matter injury: cytokine antagonists (IL-1receptor antagonist) (Hagberg et al,
1996), platelet activating factor (PAF) antagonist (Liu et al, 1996; Zhang et al, 1994) and
induced neutropenia (Hudome et al, 1997). Corticosteroids theoretically may interrupt the
inflammatory cascade that occurs during H-I; experimental and epidemiological studies
support a protective role for antenatal steroids against PWMD (Whitelaw & Thoresen, 2000;
O’Shea & Doyle, 2001), but this beneficial effect must be weighed against the adverse effects
during a critical period of brain development of postnatal high-dose steroids used to prevent
or to treat chronic lung disease in premature infants (Baud et al, 2004). Early synthetic
glucocorticoid dexamethasone (DEX) exposure may lead the neonatal brain to be more
vulnerable, exacerbated HI-induced injury on P7 by a glucocorticoid receptor-mediated
mechanism. The aggravating effect of neonatal DEX treatment on HI-induced brain injury was
correlated with decreased glutamate transporter-1 (GLT-1)-mediated glutamate reuptake.
• Minocycline (FDA Approved)
Minocycline is a semisynthetic second-generation tetracycline and a potential neuroprotective
intervention following brain injury. However, despite the recognized beneficial effects of
minocycline in a multitude of adult disease states, the clinical application of minocycline in
neonates is contentious. Tetracyclines are broadspectrum antibiotics that have antiinflamma‐
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tory effects independent from their antimicrobial activity, but, as a class, are not usually
administered to neonates. Minocycline inhibited microglial activation, reduces inflammation
and protected neurons against ischemia in adult and developing rats in several studies
(Yrjanheikki et al, 1999; Fan et al, 2006, Buller et al, 2009; Lechpammer et al, 2008). Minocycline
treatment prevents the formation of activated caspase-3, a known effector of apoptosis, as well
as the appearance of a calpain cleaved substrate, a marker of excitotoxic/necrotic cell death
(Arvin etal, 2002). Although another study found that minocycline exacerbated H-I cortical
injury in neonatal mice (Tsuji etal, 2004). Nevertheless, minocycline is not without clinical
hazard, and further study of this agent and related analogs is needed (Volpe et al, 2011).
6.2.6. Anti-apoptotic drugs
One of the hottest topics in neurobiology is apoptosis, the highly orchestrated and possibly
“controllable form of cell death” in which cells enter into a programmed suicide by chopping
themselves into membrane-packaged bits. In stroke, neurons in the penumbra zone, deprived
of oxygen and glucose tissue, gradually die because ischemic injury triggers their suicide
programmes (Miller & Marx, 1998; Barinaga, 1998). Control of apoptosis involves a balance
between expression of numerous apoptotic and anti-apoptotic proteins after injury, providing
many potential approaches to modifying outcome (blockade of downstream effects).
• Erythropoietin (EPO) (FDA Approved)
EPO is a 165 amino acid glycoprotein produced mainly by peritubular cells in the adult kidneys
and by hepatocytes in the fetus. EPO acts on the later stages of erythroid progenitor cells
development, allowing maturation of erythroid precursors by inhibiting apoptosis and thus
regulating red cell production. Recombinant human EPO (rhEPO) is currently effective and
widely used to treat anemia of prematurity. Epo, the major haemopoietic growth factor, is now
considered to have beneficial effects in various nervous system disorders based on the effects
of prevention of metabolic compromise, neuronal and vascular degeneration, and inflamma‐
tory cell activation (Maiese et al, 2008). EPO is required for normal brain development in
mammals (Juul, 2002; Yu et al, 2002). Exogenously administered EPO exhibits neuroprotective
effects in numerous animal models, through the activation of anti-apoptotic, anti-oxidant and
anti-inflammatory pathways as well as through the stimulation of angiogenic and neurogenic
events. (for a review see Kumral A et al, 2011; Juul,2012; Subirós et al, 2012). Moreover, EPO
reduced the excitotoxic effect of glutamate and AMPA upon cortical neuron cultures (Sinor &
Greenberg, 2000). EPO also prevented apoptosis induced by NMDA or by NO in neurons of
cerebrocortical cultures (Digicaylioglu & Lipton, 2001).
Recombinant human EPO (rhEPO)- induced neurogenesis has been studied in ”in vivo”
and ”in vitro” experiments, it has been shown that EPO regulates neurogenesis in the adult
mouse brain (Shingo et al, 2001). Epo is not an appropriate antenatal therapy because it hardly
crosses the human placenta (Widness et al, 1995). The capability of EPO to cross the BBB after
systemic administration and its effective therapeutic window are advantages for H-I therapy.
It requires small volumes, so it does not impose a fluid burden. The most commonly used
treatment regimens used to stimulate erythropoiesis in neonates is 400 U/kg 3 times a week
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given subcutaneously or 200 U/kg daily given IV. The optimal dose, number of doses, or dosing
interval for Epo neuroprotection in humans have not yet been determined. Neonatal Epo
treatment has been studied in randomized controlled trials of erythropoiesis, with few
reported adverse effects, and the medication is thought to be safe at doses ranging as high as
2100 units/kg/week (Fauchere et al, 2008; Juul et al, 2008). Complications seen in adults (eg,
hypertension, clotting, seizures, polycythemia, and death) (Ehrenreich et al. 2009) have not
been observed in infants. Angiogenesis may be an important adverse effect in preterm infants
at risk for retinopathy of prematurity. The first trial with EPO in full term neonates with
moderate to severe H-I demonstrated that it reduced death and disability at 18 months from
44% (controls) to 25% (EPO-treated) with no adverse effect (Zhu et al, 2009). Human trials are
just beginning, but they show promise (Elmahdy et al, 2010; Lakic et al, 2010).
Elmahdy et al (Elmahdy et al, 2010) in a prospective case-control study with 45 neonates, of
which 15 were infants with mild/moderate HIE, received human recombinant EPO (2500
IU/kg, subcutaneously, daily for 5 days), demonstrated the feasibility of early administration
of EPO to neonates with HIE for protection against encephalopathy.
• EPO-Mimetic Peptides (Not FDA Approved)
The possibility of developing Epo-mimetic that have specific subsets of Epo characteristics has
been of great interest, because these molecules might circumvent unwanted clinical effects or
provide improved permeability with the ability to cross the placenta or BBB. The tissue
protective functions of Epo can be separated from its stimulatory action on hematopoiesis, and
novel Epo derivatives and mimetics, such as asialo-Epo and carbamylated- Epo, have been
developed. No studies have been done to assess safety or efficacy of these compounds as
perinatal treatments (see Robertson et al, 2012).
Neuro-EPO is a variant with a low-sialic acid content and a short half-life. Drug transport from
the nasal cavity directly to the brain has been shown to be feasible, even for challenging drugs
such as small polar molecules, peptides and proteins, in animals and humans. Intranasally
administered Neuro-EPO exhibits neuroprotective effects in gerbil models of brain ischemia.
The use of the nasal route as a new delivery pathway to the brain is aimed to achieve quick
delivery of neuroprotective concentrations to the nervous tissue using small drug doses (see
Subirós, 2012).
• Neurotrophic factors (Neurotrophins)
Trophic factors are emerging as potential cytoprotective agents, although their role may be
more important in the recovery phase (Labiche & Grotta, 2004). Neurotrophins are important
cues for the migration and differentiation of neural stem cells (SCs). Neurotrophins are a family
of growth factors that act through tyrosine kinase receptors and regulate the development and
maintenance of brain cells by affecting growth, differentiation, maturation, maintenance and
neuronal survival, as well as synaptogenesis and brain plasticity. They also exhibit neuropro‐
tective activity in multiple neuronal populations after injury. The first neurotrophin discov‐
ered was neuronal growth factor (NGF). Further work identified other members of the family
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such as Glial Derived Neurotrophic Factor (GDNF), Brain Derived Neurotrophic Factor
(BDNF), and Neurotrophin-3 (NT-3).
The neurotrophins play a vital role in development, but also in the maintenance of the neuronal
systems throughout life (Sizonenko et al, 2007). During the neonatal period, neurotrophins
and their receptors are essential for brain development. After brain insult, neurotrophins levels
increase, suggesting that they have an endogenous protective mechanism that limits neuronal
cell death. Since discovery of the potent survival-promoting effects of neurotrophic factors
(possibly through angiogenic mechanisms), they have been proposed as potential tools to be
tested for the treatment of diseases of the CNS (e.g.: basic fibroblast growth factor-bFGF)
(Binder & Scharfman, 2004). The protection of neurons, and perhaps most cells, from excito‐
toxicity and H-I injury may require extracellular ligand–receptor interactions and the activa‐
tion of specific intracellular signaling cascades. In the CNS, these signals are provided, at least
in part, by neurotrophic growth factors. Several neurotrophic factors (such as platelet-derived
growth factor, insulin-derived growth factor, and glial cell line-derived neurotrophic
factor) that have been reported to protect against excitotoxicity and H-I injury in immature
animal models may act by inhibiting apoptosis (Nozaki et al, 1993; Hossain et al, 1998; Wang
et al, 2013), these have not been studied in humans. Neurotrophins could guide migration and
differentiation of stem cell transplants after brain injury, and once at the site of injury, enhance
neuronal differentiation (Douglas-Escobar et al, 2012).
• Neuropeptide-inhibitor
Neuropeptides modulate neuronal activity and may therefore modulate glutamate-induced
neuronal cell death. Neuropeptides are inactivated by enzymatic proteolysis, indicating that
proteolysis inhibition may hold therapeutic potential. Among the peptidases identified, neural
endopeptidase (NEP or neprilysin) is involved in the regulation and metabolism of a variety
of biologically active peptides including tachykinins/ neurokinins (see Degos, 2008). Interest‐
ingly, the NEP inhibitor Racecadotril (Tiorfan®) is used in clinical practice to treat diarrhea,
with a remarkably good safety profile. Racecadotril is rapidly and entirely metabolized to its
active metabolite thiorphan. A recent study showed that systemic administration of thiorphan
was neuroprotective against excitotoxic neuronal cell death in newborn mice (Schwartz,
2000). This neuroprotective effect was long-lasting and was still observed when thiorphan was
administered 12 h after the insult, indicating a wide window for therapeutic intervention
(Medja et al, 2006).
6.3. Neurorestorative therapies
There is increasing evidence from “in vitro” and “in vivo” preclinical studies that stem/
progenitor cells may have multiple beneficial effects on the outcome after H-I injury. Stem cell
(SCs) treatment can be administered by stimulating endogenous SCs (neurotrophic factors/
growth factors such as EPO, insulin-like growth factor and brain-derived neurotrophic factor)
or by transplanting exogenous SCs. Stem/progenitor cells (umbilical cord SCs, mesenchymal
stromal cells, and bone marrow mesenchymal SCs) have been used for the experimental
treatment of neonatal HIE models, and have shown great promise in animal studies in
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decreasing neurological impairment. Neural stem/progenitor cells (NSCs) have also been
transplanted in animal models of HIE, migrating long distances to ischemic brain areas and
differentiating into neurons. SCs therapies are one of the promising options for the treatment
of neonatal neurological diseases in the future. However, the mechanisms of action of the SCs,
and the optimal type, dose, and method of administration remain surprisingly unclear, and
some studies have found no benefit. Although cell-based interventions after completion of the
majority of secondary phase cell-death appear to have potential to improve functional outcome
for neonates after HI, further rigorous testing in translational animal models is required before
randomized controlled trials should be considered. (Review articles: Pimentel-Coelho &
Mendez-Otero, 2010; Bennet et al, 2012; Pabon et al, 2013). Additionally, their clinical use is
strongly limited by the existence of the BBB that makes the human brain refractory to targeting
of cell-sized agents delivered through the peripheral system. Intracerebral transplantation to
bypass the BBB is a very invasive delivery method that cannot be proposed for human
newborns.
• Cord blood: Umbilical cord blood cells (UCBCs), which are readily available at birth, have
been shown to reduce sensorimotor and/or cognitive impairments in several models of brain
damage, representing a promising option for the treatment of neurological diseases. The
possible cell types and mechanisms involved in the therapeutic effect of UCBC transplan‐
tation, including neuroprotection, immunomodulation and stimulation of neural plasticity
and regeneration have been recently reviewed by Pimentel-Coelho et al. (Pimentel-Coelho
et al., 2012).
• Mesenchymal stem cells (MSC): The beneficial effect of MSC transplantation to treat
neonatal brain injury might be explained by the great plasticity of the neonatal brain. The
neonatal brain is still in a developmentally active phase, leading to a better efficiency of MSC
transplantation than that observed in experiments using adult models of stroke. Enhanced
neurogenesis and axonal remodeling likely underlie the improved functional outcome
following MSC treatment after neonatal H-I brain injury. With respect to the mechanism of
repair by MSCs, MSCs do not survive long term and replace damaged tissue themselves.
MSC treatment after H-I reduced contralesional rewiring taking place after HI and increased
the connection between the impaired forepaw and the ipsilesional motor cortex. These
intrinsic adaptive properties of MSCs make them excellent candidates for a novel therapy
to treat the devastating effects of HIE in the human neonate (van Velthoven et al, 2012).
Intranasal MSC treatment may become a promising non-invasive therapeutic tool to
effectively reduce neonatal encephalopathy (Donega et al, 2013).
• Neural stem/progenitor cells (NSCS): NSCs have also been transplanted in animal models
of HIE, migrating long distances to ischemic brain areas and differentiating into neurons
(Llado et al, 2004). The survival of transplanted NSCs was limited in these experiments for
several potential reasons (Sato et al, 2008).
• Adipose stromal cells (ASC): In a rat middle cerebral artery occlusion model of ischemic
brain injury, intracerebral transplantation of human ASC was followed by migration of these
cells to areas of ischemic damage and by expression of neuronal specific markers in
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conjunction with functional benefit. Therefore, the use of ASC could have potential to
develop treatments to reverse or prevent the effects of H-I injury. (Kang et al, 2003)
7. Combined therapy
Following HIE, a complicated cascade of pathophysiologic processes is unleashed including
excitotoxicity, oxidative stress, inflammation, and cell death via necrosis and apoptosis. These
processes can lead to long-term neurologic injury. The post-injury time course can be divided
into a latent (0–6 hours), secondary (6–72 hours) and tertiary phase (>72 hours) (Perlman,
2011). Studies in laboratory animals have shown that the immature brain responds differently
to treatment than does the mature brain, which leads us to believe that an optimal treatment
for a neonate would differ from that for a toddler and probably none of them would be the
best option for an adult. Specific vulnerabilities that distinguish the response of the immature
brain from that of the mature brain include:
Primary/latent phase (0–6 hours)
• Greater neuronal metabolism: The neonatal brain has a high rate of oxygen consumption.
Such energetic costs seem also to exert a selective pressure towards metabolically efficient
neural morphology, leading to metabolically efficient patterning of dendritic arborizations,
neural codes and brain wiring patterns (Holliday, 1986).
• Antioxidant system insufficiency.
• The NMDA receptor subunits in the developing brain open more easily and block less
frequently than mature forms, responsible for the fact that immature brains are far more
excitable and epileptogenic than the adult brain.
Secondary phase (6–72 hours)
Increased susceptibility to excitotoxicity and FR injury, due to the production of large amounts
of FR, high concentrations of PUFAs, and antioxidant system insufficiency (Grow & Barks,
2002).
Tertiary phase (>72 hours)
• Greater tendency to apoptotic death: activation of apoptosis-executing caspases is much
greater in the immature brain than in the adult brain. During the tertiary phase, neurons
and glial cells are lost due to chronic loss of trophic factors, loss of synaptic input from
neighboring cells, and loss of or failure of recruitment of new progenitor neural stem cells
and glial progenitor cells (heightened vulnerability of immature OL). Cell death involving
a cell-autonomous active contribution of catabolic enzymes (or apoptosis) plays a prominent
role in the evolution of H-I injury in the neonatal brain and it is at least as important for the
loss of neurons as unregulated cell death (or necrosis) (Zhu et al, 2007). The prominence of
autophagic neuronal death in the ischemic penumbra and the neuroprotective efficacy of
postischemic autophagy inhibition indicate that autophagy should be a primary target in
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the treatment of neonatal cerebral ischemia (Puyal etal, 2009). Therapy designed to ameli‐
orate brain injury in adults may worsen outcomes in neonates, possibly by accentuating the
apoptotic cell death cascade.
Neurogenetic and gliogenetic processes after H-I injury: neuroblast proliferation and migra‐
tion from the neurogenetic niches take place after the lesion. Some cells differentiate into
neurons (neuronal differentiation) and migrate to the injured area. Some other cells from the
SPZ give rise to radial glia that contribute to neural progenitor expansion and support
neuroblast migration. Thus, the neuronal elements in the transient fetal zones represent a
potential for plasticity after perinatal cerebral lesions and neuronal migration could play a
central role in brain repair (Kostovic & Judas M, 2006, Cayre et al, 2009, Distefano and Praticò,
2010). It is possible that the same chemical mediators that have deleterious effects during the
initial stages of ischemia may also be involved in the ulterior process of neurorestoration.
Therefore, the lack of effect found for some neuroprotective drugs could be due to either
untimely or too prolonged period of administration, thus interfering with a given metabolic
route at the time that is involved in the endogenous mechanisms of repair (Lo, 2008).
With the advent of hypothermia as therapy for term HIE, there is hope for repair and protection
of the brain after a profound neonatal insult. However, hypothermia alone would not be
sufficient to provide the required protection or stimulate the repair to ensure a normal
neurodevelopment. Based on the theory of “secondary energy failure”, hypothermia may
provide the possibility to “buy time”, in order to successfully use other (pharmacologic)
interventions, by preserving energy metabolism elongating the therapeutic time window
(Gunn & Gunn, 1997). At present, no individual neuroprotective agent has been proven safe
and effective for the protection of neonates from neurological sequels after H-I insults as
monotherapy. The persistent clinical failures might be due to many factors, including:
heterogeneity in the causes of neural death in humans, associated toxicity at the doses required
for drug-efficacy, the lack of adequate CNS penetration across the BBB and or the limited time
window available to start the treatment (in real-life clinical practice, delays in the initiation of
therapy are difficult to avoid).
Since there are many mechanisms involved in H-I process, it is reasonable to assume that the
combination of several drugs or the use of molecules that combine two or more neuroprotective
actions can exert synergistic effects by blocking diverse metabolic pathways. Traditionally, the
above mentioned simultaneous drug co-administration has been discouraged, since it involves
potential risks of interference, side effects and error in the sequence of administration.
However, the use of hypothermia plus adjuvant therapies has been extensively reviewed (Cilio
& Ferrriero, 2010; Robertson et al, 2012; Buonocore et al, 2012; Shankaran, 2012). According to
the existing literature, the combined therapy of hypothermia and other neuroprotective
strategies would be expected to increase the therapeutic time window, enhance neural repair
and improve the neurological outcomes of HIE. Although both clinical observations and
animal experimentation suggest that the cascade of damaging events in the developing brain
may last for several days -thus extending the window of opportunity for intervention- the most
successful outcome is likely to result from the earliest possible delivery of therapy (Rees et al,
2011). Few studies have examined possible interactions of medications with hypothermia and
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whether combination therapies augment neuroprotection. Based on the preclinical studies,
ongoing trials in neonates include: inhaled xenon and cooling (NCT01545271 and
NCT00934700), safety of erythropoietin (NCT00719407), darbepoetin and hypothermia
(NCT0147105), and topiramate plus hypothermia (NCT01241019).
Additional neuroprotective strategies to combat perinatal brain injury are urgently needed
that may be used as possible synergies for therapy. Presumably the best outcome will be
achieved by a multi-modal therapeutic approach such as a combination of hypothermia with
anti-oxidants and glutamate receptor antagonists, using drugs with multiple effects (affecting
multiple injury cascades and with neuroregenerative potential) without toxicity, no apparent
interaction and previously used in children. Furthermore, the timing of the administration of
medication may be critical to optimize the benefits and avoid neurotoxicity (e.g., early acute
treatments targeted at amelioration of the neurotoxic cascade compared with subacute
treatment that may promote regeneration and repair) (Kelen & Robertson, 2010).
8. Staggered design for a “off-label* combined therapy”
Given the urgency to find better therapies for HIE, and in the absence of ongoing clinical trials,
we propose a model of “off-label therapy” based on hypothermia /antiepileptic drugs in
combination with antioxidants, phospholipase A2 inhibitors, glutamate receptor antagonists
and EPO using a staggered design in function of the intensity of the perinatal asphyxia and
severity of the encephalopathy. However, we believe that a multicenter interventional
randomized controlled pilot phase II clinical trial would be necessary.
Premises
• All drugs have been approved by the FDA.
• All the drugs have been currently available in infants without serious side effects.
• All drugs have demonstrated neuroprotection
• All drugs have and synergy with hypothermia, increasing the neuroprotective efficacy of
therapeutic hypothermia in perinatal H-I brain injury – animals/clinicals- models.
• All drugs have different mechanisms and multiple potential modes of action.
Timing of the administration of medications:
At the time of initiation of hypothermia, stage 1 drugs would also be administered for at least
72 hours. If moderate / grave encephalopathy (according to clinical and encephalographic
evaluation) persists, administration of the drugs assigned to the next stages would successively
proceed. It should be noted that the use of hypothermia delays the pathophysiological
response to H-I (postpones secondary energy failure) and therefore “widens” the therapeutic
window. This phenomenon allows staggering the application of the adjuvant drugs, thus
providing the physician with the necessary time to assess the clinical situation of the patient
and decide whether to proceed to the next therapeutic phase.
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8.1. Primary/latent phase (0–6 hours)
• Anticonvulsants for neonatal seizures: PHENOBARBITAL: PB remains the preferred drug
for the treatment of seizures in neonates with HIE. Ways of action: anticonvulsant effects
by increase GABA subtype A (GABAA)-receptor channel chloride currents, reduced
cerebral metabolic demand, antioxidant effects and decreased cerebral edema. Doses:
loading dose 20 mg/kg IV, followed by 3- 5 mg/kg/day, every 12 hours
• Antioxidative drugs: Free radical nonenzymatic scavengers (N-acetylcysteine and
Vitamin E)
• N-acetylcysteine (NAC). Ways of action: act as an anti-oxidant and is also a scavenger of
oxygen FRs, reduce oxidative stress and inflammation; prevents endotoxin-induced
degeneration of OL progenitors and hypomyelination; attenuated activation of apoptotic
proteases.
Continuous IV infusion, by simplified N-acetylcysteine dosing regimen – Standard prepara‐
tion of IV-
Prepare standard solution IV: 50ml NAC 20% + 200ml SG5% (5% dextrose in water) = Solution
NAC 40mg/ml. Doses: 150mg/kg (3,75ml x kg) IV loading dose administered over 1 hour,
followed by an infusion of 12 mg/kg/h (7.2ml x Kg) for 24 hours. Continue with infusion of
150 mg/kg/24 h (3.75 ml x Kg) for 24 hours, to complete 72 hours
Or 72-hour oral-NAC: 140 mg/kg of oral NAC followed by 70 mg/kg every 4 h. for an additional
17 doses.
• Vitamin E. Ways of action: protects OL during this special vulnerability maturation period
from the oxidative stress-induced death caused by glutathione depletion. It also ameliorates
secondary mitochondrial failure. Doses: 50 U.I. orally, followed by 1 UI/kg/24 hours.
Equivalency: 1 U.I. Vitamin E = 1 mg tocopherol acetate.
8.2. Secondary phase (6–72 hours)
• Antiexcitatory drugs: Topiramate. Ways of action: blocking sodium channels, high voltage-
activated calcium currents, enhancing GABAinduced influx of chloride, and inhibiting
kainite/ AMPA glutamate receptors. It also to blocks carbonic anhydrase isoenzymes and
the mitochondrial permeability transition pore. Doses: 10 mg/kg/24 hous, divided into 2
doses, orally administered by orogastric tube.
• Bioactive lipid mediators: Citicoline. Ways of action: Neuroprotective effects - decrease
of phospholipase A2 stimulation and hydroxyl radical generation; increase of glutathione
synthesis and glutathione reductase activity, restoration of Na+/K+-ATPase activity, and
antiglutamatergic effects. Roles in the generation of phospholipids involved in membrane
formation and repair; prevention of fatty acid release, stimulation of phosphatidylcholine
synthesis, preservation of cardiolipin and sphingomyelin levels. Neuroregenerative effects
- related to inhibition of the glutamate induced apoptotic pathway, markedly reduces
caspase-3 activation; increases neurogenesis in the SVZ and migration of neural progenitors
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to the lesion area with increased neurogenesis also within the peri-infarct area. Dosis: 100
mg/kg/24 hours, every 12 h, intravenously during the first 3 days, and orally administered
by orogastric tube thereafter for a total of 6 weeks.
8.3. Tertiary phase (>72 hours)
• Anti-apoptotic drugs: Erythropoietin (EPO). Ways of action: Neuroprotective effects -
activation of anti-apoptotic, anti-oxidant and anti-inflammatory pathways as well as
through the stimulation of angiogenic and neurogenic events; reduces the excitotoxic effect
of glutamate and a glutamate receptor agonist (AMPA) on cortical neuron cultures.
Neuroregenerative effects - prevents apoptosis induced by NMDA or by NO in neurons
from cerebrocortical cultures and regulates neurogenesis. Dosis: Recombinant human EPO
(rhEPO) given subcutaneously 400 U/kg daily for 5 days, thereafter 3 times a week.
9. Conclusion
Since hypoxic ischemic encephalopathy (HIE) is a potentially preventable cause of cerebral
palsy (CP), much interest has been focused on prevention as well as research on neuroprotec‐
tion therapies. Neuroprotective treatment for HIE in the clinical practice has been limited to
the application of hypothermia in the newborn which is now accepted as a significant therapy,
since so far no drug has shown any benefit when administered on its own. However, hypo‐
thermia alone may not provide complete protection or stimulate the repair that is necessary
for a normal neurodevelopmental outcome. As we have described in this chapter, many
mechanisms can be involved in the H-I process. It is therefore a reasonable assumption that
the combination of several drugs involving two or more neuroprotective actions may exert
synergistic effects by tackling several metabolic pathways at one time. We propose a model of
“off-label combined therapy” based on hypothermia /antiepileptic drugs in combination with
antioxidants, phospholipase A2 inhibitors, glutamate receptor antagonists or EPO using a
staggered design in function of the intensity of the perinatal asphyxia and severity of the
encephalopathy.
Note
*”Off- label” use is the use of already authorized pharmaceutical drugs for an unapproved
indication or in an unapproved age group, unapproved dosage, or unapproved form of
administration.
The term “compassionate use” (also known as compassionate exemption or expanded access) is used
to define treatment options that allow the use of an unauthorised medicine. It may be applied
to patients who cannot be treated satisfactorily by an authorised medicinal product or cannot
enter a clinical trial. Although sometimes “off label use” has been considered a type of
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“compassionate use”, those two concepts should not be mistaken since they have different
legal requirements. For reference and discussion see:
• Randall S. Stafford. "Regulating Off-Label Drug Use — Rethinking the Role of the FDA". N
Engl J Med 2008; 358: 1427–1429.
• Bombillar-Sáenz F.M. “The “Compassionate Exemption” In Spain: Not Asking For Com‐
passion, Op. J., Vol. 2/2010, Paper n. 1, pp. 1 - 25, http://lider-lab.sssup.it/opinio, online
publication July 2010.
• Guideline on compassionate use of medicinal products, pursuant to article 83 of regulation
(EC) No 726/2004. Doc. Ref: EMEA/27170/2006.
Abbreviations
AA arachidonic acid
AEDs antiepileptic drugs
ALLO allourinol
AMPAalfa-amino-3-hydroxy-5-methyl-4-isoxazole-
propionic acid
BBB blood-brain barrier
CBF cerebral blood flow
CBFV cerebral blood flow velocity
CAT catalase
CSF cerebrospinal fluid
CNS central nervous system
CP cerebral palsy
DC dendritic cell
DEX dexamethasone
EAA excitatory amino acid
EPO erythropoietin
FDA Food and Drug Administration (USA)
FFA free fatty acids
FR free radical
GPX glutathione peroxidase
H-I hypoxic–ischemic
HIE Hypoxic ischemic encephalopathy
IL interleukins
I/R ischemia/reperfusion
IV intravenous
IVH intraventricular hemorrhage
LPS lipopolysaccharide
MBP myelin basic protein
NAC N- acetyl-l-cysteine
NICU Neonatal Intensive Care Unit
NMDA N methyl-D-aspartate
NO nitric oxide
NOS Nitric oxide synthase
NT's neurotransmitters
OL oligodendrocyte
PAF platelet activating factor
PB Phenobarbital
PLA2 phospholipase A2
Pre-OL premyelinating oligodendrocyte
PUFAs polyunsaturated fatty acids
PVL periventricular leukomalacia
PWMD periventricular white matter damage
PCW postconceptional weeks
RNS reactive nitrogen species
ROS reactive oxygen species
SCs Stem cell
SNN selective neuronal necrosis
SOD superoxide dismutase
SPZ subplate zone
SVZ subventricular zone
TLR toll-like receptor
TPM Topiramate
VLBW very low birth weight
WM white matter
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